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ABSTRACT
Solid tumors have a microenvironment that is inherently acidic and hypoxic. Hypoxia
is caused by leaky blood vessels and large diffusion distances from cells to them. It is
heterogeneous throughout the tumor and while all solid tumors are hypoxic to a
degree, it is difficult to predict invasiveness based on it. However, acidity is a near
ubiquitous characteristic of tumors with more aggressive tumors producing greater
acidity. It is important to measure pH in diseased tissue with accuracy and precision,
since acidity is associated with the development of various pathological states
including tumors. In this work we focus on the acidosis aspect of the tumor
microenvironment by describing the development of pHLIP (pH (Low) Insertion
Peptides) targeting based tools that are capable of imaging the pH of a tumor
microenvironment. pHLIP was chosen as a targeting vehicle because of its pH
dependent insertion mechanism that allows it to effectively target acidic tissues,
including tumors.

We used pHLIP® to study the roles of carboxyl groups in transmembrane (TM)
peptide insertion. pHLIP binds to the surface of a lipid bilayer as a disordered peptide
at neutral pH; when the pH is lowered, it inserts across the membrane to form a TM
helix. Peptide insertion is reversed when the pH is raised above the characteristic pKa
(6.0). A key event that facilitates membrane insertion is the protonation of aspartic
acid (Asp) and/or glutamic acid (Glu) residues, since their negatively charged side
chains hinder membrane insertion at neutral pH. In order to gain mechanistic
understanding, we studied the membrane insertion and exit of a series of pHLIP
variants where the four Asp residues were sequentially mutated to nonacidic residues,

including histidine (His). Our results show that the presence of His residues does not
prevent the pH-dependent peptide membrane insertion at ∼ pH 4 driven by the
protonation of carboxyl groups at the inserting end of the peptide. We expect that our
understanding will be used to improve the targeting of acidic diseased tissue by
pHLIP.
Looking from the lipid bilayer’s perspective, small angle x-ray scattering studies
showed membrane thinning by 18% induced by insertion of short-pHLIP (truncated
version of pH Low Insertion Peptide) into bilayer. Thinning allows to reduce stress on
membrane associated with negative hydrophobic mismatch. Also we observed 12% of
membrane thinning when long-pHLIP partitions into outer leaflet of bilayer at high pH
adopting coil conformations. The long-pHLIP at high pH creates an asymmetric
inclusion in the bilayer, which results in increase of tension leading to the bilayer
thinning. The tension and thinning is released when long-pHLIP inserts into bilayer as
a transmembrane helix at low pH.

The first tool developed is a new
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Cu-pHLIP peptide for targeting, imaging and

quantifying acidic tumors by positron emission tomography, and our findings reveal
utility in assessing prostate tumors. The new pHLIP version limits indiscriminate
healthy tissue binding, and we demonstrate its targeting of extracellular acidification
in three different prostate cancer models, each with different vascularization and acidextruding protein carbonic anhydrase IX (CAIX) expression. We then describe the
tumor distribution of this radiotracer ex vivo, in association with blood perfusion and
known biomarkers of acidity such as hypoxia, lactate dehydrogenase A and CAIX. We

find that the new probe reveals metabolic variations between and within tumors, and
discriminates between necrotic and living tumor areas.

The second tool introduced is a novel approach of extracellular pH measurements at
the surface of cells, which is based on the use of a pH-sensitive fluorescent dye
SNARF conjugated to a pH Low Insertion Peptide (WT-pHLIP), which targets plasma
membranes of cells in acidic diseased tissue. Our experimental set up includes two
different approaches, one is based on acquisition of fluorescent spectra, and other one
is based on recording of images via two emission filters. By using appropriate
calibration curves obtained on liposomes and tumor spheroids in the presence of 2deoxyglucose, both approaches give the same values of surface pH. The developed
tool was validated on cancer cells grown in tumor spheroids, in mice and excised
tumors ex vivo. We establish that highly metastatic cancer cells have lower pH at their
surface compared to non-metastatic cells. Our approach was sensitive enough to detect
pH changes in vitro and in vivo induced by glucose, which leads to the enhancement
of cancer cells metabolism and acidification of the extracellular space. The introduced
tool could be developed for clinical application of surface pH measurements in biopsy
samples. It might provide important clinical information about tumor stage and
invasiveness, and can guide in the choice of treatment approach.
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pH at the surface of cancer cells measured in vitro, in vivo and ex vivo. In
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Roles of Carboxyl Groups in the Transmembrane Insertion of Peptides
Francisco N. Barrera1, Dhammika Weerakkody2, Michael Anderson2, Oleg A.
Andreev2, Yana K. Reshetnyak2, Donald M. Engelman1
1
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2

Physics Department, University of Rhode Island, Kingston, RI 02881, USA

Research Highlights

pHLIP forms a TM helix at acidic pH. We mutate all aspartic acid residues. His
residues do not prevent pH-dependent peptide membrane insertion. The number of
residues that protonate correlates with insertion cooperativity.

Abbreviations

TM, transmembrane; wt, wild type; POPC, 1-palmitoyl-2-oleoyl-sn-glycero-3phosphocholine; OCD, oriented circular dichroism; PEG, polyethylene glycol; pH,
extracellular pH

Keywords
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Abstract
We have used pHLIP® [pH (low) insertion peptide] to study the roles of carboxyl
groups in transmembrane (TM) peptide insertion. pHLIP binds to the surface of a lipid
bilayer as a disordered peptide at neutral pH; when the pH is lowered, it inserts across
the membrane to form a TM helix. Peptide insertion is reversed when the pH is raised
above the characteristic pKa (6.0). A key event that facilitates membrane insertion is
the protonation of aspartic acid (Asp) and/or glutamic acid (Glu) residues, since their
negatively charged side chains hinder membrane insertion at neutral pH. In order to
gain mechanistic understanding, we studied the membrane insertion and exit of a
series of pHLIP variants where the four Asp residues were sequentially mutated to
nonacidic residues, including histidine (His). Our results show that the presence of His
residues does not prevent the pH-dependent peptide membrane insertion at ∼ pH 4
driven by the protonation of carboxyl groups at the inserting end of the peptide. A
further pH drop leads to the protonation of His residues in the TM part of the peptide,
which induces peptide exit from the bilayer. We also find that the number of ionizable
residues that undergo a change in protonation during membrane insertion correlates
with the pH-dependent insertion into the lipid bilayer and exit from the lipid bilayer,
and that cooperativity increases with their number. We expect that our understanding
will be used to improve the targeting of acidic diseased tissue by pHLIP.
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Introduction
Extracellular acidification is a hallmark of different pathologies, including cancer,
inflammation, ischemic stroke, and atherosclerotic plaques. Acidosis might be a useful
biomarker for diagnosis or treatment if means can be found to target tissue acidity. We
have found that a peptide derived from helix C of bacteriorhodopsin,1 named pHLIP®
[pH (low) insertion peptide], is capable of targeting acidic tissues and inserting into
the cell plasma membrane.2 pHLIP is able to target mouse tumors in vivo with high
specificity,2 opening the possibility of its use for cancer imaging. Additionally, pHLIP
has a promising therapeutic potential, as it is able to translocate cell-impermeable
cargo molecules, such as organic dyes, peptides, peptide nucleic acids, and toxins,
across the plasma membrane into the cytoplasm of tumor cells. 2 and 3 pHLIP itself does
not have obvious acute toxicity in cells3 or in mice.2

pHLIP is monomeric at low concentrations, with a mostly unstructured conformation
in neutral and basic solutions (state I). If lipid vesicles or membranes are present at
neutral pH, pHLIP binds to their external surface with an energy of 6–7 kcal/mol (state
II).4 In the membrane-attached state, pHLIP remains largely unstructured.1 However,
if the solution pH is lowered, pHLIP inserts to form a transmembrane (TM) α-helix
(state III). The insertion is fully reversible and unidirectional, with the C-terminus
being translocated across the membrane.3 The pKa of peptide insertion into lipid
bilayers is 6.0, and the energy difference between the attached state and the inserted
state is 1.8 kcal/mol at 37 °C.4
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The pHLIP sequence is relatively rich in acidic residues (Table 1). At neutral pH, the
combined negative charges of these residues, together with the carboxy terminus,
constitute a large energetic barrier to pHLIP insertion across the membrane. The
estimated energetic cost of the transfer of a single aspartic acid residue from water to
the hydrophobic core of the membrane is unfavorable by 3.6 kcal/mol for the
unprotonated (negatively charged) state, but only by 0.4 kcal/mol for the protonated
(noncharged) state.5 Simultaneously moving four charged Asp residues, one Glu
residue, and the carboxy terminus into the membrane would cost 21.6 kcal/mol,
assuming 3.6 kcal/mol for each carboxyl group, and peptide partitioning into the
membrane at equilibrium would be about 1:1016. Thus, for pHLIP to be able to insert
into membranes, protonation of a large fraction of the acidic residues can be expected,
and knowledge of the protonation pattern of the acidic residues of pHLIP is an
essential part of understanding the molecular mechanism of the membrane insertion
process for any peptide containing carboxyl groups. Two classes of carboxyl groups
are of interest: those that remain buried in the membrane after pHLIP is inserted into
the membrane and those that traverse the hydrophobic core of the membrane during
insertion.6 Accordingly, we have studied both the pH-driven membrane insertion and
the exit process for a series of peptides where the key aspartic acid residues are
sequentially mutated.

4

Results

Previous studies in our laboratories revealed that sequence variations in the TM region
of pHLIP can disrupt the delicate balance that preserves its water solubility. For
example, a simultaneous change in the two aspartic acid residues at positions 14 and
25 to the homologous glutamic acid (Asp14/25Glu) resulted in a loss of pH-dependent
membrane insertion due to aggregation of the peptide in aqueous solution7 (we have
recently developed new pHLIP variants with several Glu residues, which preserve pHdependent properties; unpublished data). In order to reduce the likelihood that the
introduced variations in the peptides used in this work could cause aggregation, we
decided to follow a dual strategy to increase their water solubility: (i) we added an Asp
tag to the N-terminus (noninserting end) to increase the number of charges in the
molecule, which typically improves the solubility of hydrophobic peptides8 and 9; this
resulted in the replacement of the N-terminal sequence AAEQ with DDDED
(Table 1); and (ii) we used the TANGO algorithm10 to define the region of the pHLIP
sequence with the highest aggregation tendency and found this to be the stretch from
residue 21 to residue 30 (coinciding with the most hydrophobic region of the peptide).
We then mutated Leu26 to Gly, which greatly reduced the predicted aggregation
tendency.

We incorporated these modifications into a series of pHLIP variants, where four
aspartic acid residues were sequentially mutated to nonacidic polar residues. The
aspartic acid residues at the C-terminus of the peptide that transitorily traverse the core
of the membrane upon insertion (Asp31 and Asp33) were replaced with polar but
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uncharged asparagine residues. On the other hand, for the Asp residues that are located
in the core of the membrane after insertion (in positions 14 and 25), histidine was
chosen as the replacement residue, as it is expected to be partially charged at neutral
pH (thus improving water solubility) while being only slightly polar in its uncharged
state (the transfer energies from water to the bilayer interior are 0.43 and
0.11 kcal/mol for the neutral forms of Asp and His,5 respectively) so that the insertion
properties of pHLIP may not be altered. The peptides were named D0–D3 according
to the number of aspartic acid residues present in the regions of interest (TM and Cterminus; the positively charged N-terminus is not expected to interact with the
membrane). For the variants with three aspartic acids, two alternatives were studied:
one that kept Asp14 (D3a peptide) and the other that kept Asp25 (D3b peptide).

We conducted experiments to test the state of the variants in solution, where pHLIP is
largely found as an unstructured monomer.11 Sedimentation velocity experiments were
conducted to determine the oligomerization state of the different peptide variants in
aqueous buffer. Previous analysis of wild-type (wt) pHLIP (at 7 μM in 10 mM
phosphate buffer and 100 mM NaCl, pH 8)11 showed that pHLIP is mostly
monomeric, but a small oligomer population is observed (∼ 6%). We performed our
sedimentation velocity experiments under the same conditions, but without NaCl in
the solution. For each peptide, we observed a peak with a sedimentation coefficient of
0.72 ± 0.12 S (Table 2 and Fig. 1), which corresponds to a molecular mass of
3.4 ± 0.8 kDa. This is in agreement with the expected monomer masses of the
different peptides (4126 Da for wt and ∼ 4300 Da for the different variants), with the
differences being ascribed to shape effects from the extended peptide. In the case of
6

D1 and D0, a minor peak with a sedimentation coefficient of 3.3 ± 0.3 S was also
observed. This component represents 5 ± 2% of the total population, and its
sedimentation coefficient corresponds to a molecular mass of 43 kDa (roughly
consistent with the presence of an octameric or decameric particle). Comparison of our
results with the previous report for wt suggests that the presence of oligomers is
reduced at lower ionic strength. For the particular case of the D1 and D0 peptides, they
seem to have a slightly higher oligomerization tendency in solution, but they are still
95% monomeric. Thus, our results suggest that all the peptide variants remain soluble
and are essentially monomeric. For the rest of the experiments, we employed peptide
concentrations (1.5–5 μM) lower than that used for sedimentation analysis (7 μM);
thus, the level of oligomers present for D1 and D0 is expected to be lower.

Fluorescence spectra of the peptides in aqueous solution at neutral pH showed that, in
all cases, the emission maximum is centered around 347–349 nm (Fig. 2, black lines,
and Table 2), indicating that the two tryptophan residues of the peptides are largely
exposed to aqueous solution, as in fully unfolded proteins, and consistent with the
slightly low sedimentation coefficient. This finding represents an improvement over
the previously studied Asp14/25Glu mutant peptide, where peptide aggregation shifts
the emission maximum to 342 nm in buffer at pH 8.7 A similar fluorescence maximum
was also observed for the Asp14/25Asn mutant under the same conditions.2 The
presence of mostly unstructured species in aqueous solution for each of the studied
peptides was confirmed by circular dichroism (CD) experiments, since the observed
CD spectra were characterized by a minimum at 203 nm (Fig. 3, black lines), as
observed for pHLIP in state I.
7

The two lipid-interacting states of the pHLIP variants were then examined: state II,
where wt pHLIP is mostly unstructured and attached at the bilayer surface, and state
III, where wt pHLIP forms a TM helix at low pH.1 and 6 Fluorescence experiments in
the presence of 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) liposomes
revealed that for the two D3 variants, the characteristic fluorescence signatures for
states II and III were evident: (i) in the presence of liposomes at neutral pH (Fig. 2,
blue lines), the fluorescence emission maxima of the peptides were slightly shifted
from 348.7 ± 1.0 to 346.2 ± 1.2 nm, accompanied by a small fluorescence increase
(Table 2); and (ii) when the pH was lowered to pH 4, we observed a large fluorescence
increase and a spectral blueshift to 336.2 ± 1.1 nm (red lines), which are typically
observed when the Trp side chain is buried in the membrane hydrophobic core. To
complement the fluorescence data, we performed CD experiments under the same
conditions (Fig. 3). The CD signature of the pHLIP membrane insertion process
consists of the appearance of the characteristic signals associated with the formation of
α-helix: minima at 208 and 222 nm and positive ellipticity at 190 nm. Both D3
variants showed spectral changes very similar to those observed for wt upon
acidification. Thus, we concluded that replacement of one of the Asp residues in the
TM region of the peptide does not lead to changes in the peptide's ability to interact
with the membrane in a pH-dependent manner.

The D2 variant, where both Asp residues are replaced by His residues, also
demonstrates a pH-dependent membrane interaction. However, the spectral pattern is
slightly different from those for wt and D3 variants: the fluorescence intensity of D2
in the presence of POPC decreases in the pH range 8–6, with no significant changes in
8

the spectral maximum at pH 8–7 and with a small shift to lower wavelengths at pH 6
(Fig. S1). The amount of the helical structure of D2 at neutral pH is slightly higher
than those of wt and D3 (Fig. 2 and Table 2), while no change is seen in the pH range
8–6. As an explanation, we suggest that D2 partitions somewhat more deeply into the
membrane lipid bilayer than wt and D3 at neutral pH values, since His residues are
expected to be only partially charged at neutral pH values, enhancing the
hydrophobicity of the peptide TM and its affinity for the lipid bilayer. The decrease in
fluorescence signal in the pH range 8–6 might be attributed to the partial quenching of
emission of at least one of the Trp residues by one of the partially protonated His
residues. At the same time, at neutral pH values, the peptide C-terminus containing
four negative charges (two Asp, one Glu, and the C-terminus) does not partition into
the membrane, keeping the peptide at the membrane surface. A further drop of the pH
to pH 3–4 is associated with a fluorescence spectral maximum blueshift, an increase in
fluorescence intensity (Fig. 2), and the appearance of a more pronounced negative
band at 222 nm on CD spectra (Fig. 3), which is usually an indication of peptide
insertion into the bilayer.1 Reduction of pH leads to the protonation of negatively
charged groups at the C-terminus and peptide insertion into the membrane. At the
same time, we expect that protonation of His residues at low pH should occur; this
might lead to the peptide's exit from the lipid bilayer or, alternatively, the formation of
a pore channel in the lipid bilayer, where positively charged His residues would be
pointed toward the channel. Calcein encapsulation control experiments that rule out
the formation of pores in the membrane by the D2 and D3 peptides were performed
(Fig. S2). Thus, most probably, the pKa for the protonation of His is shifted to very
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low pH values when it is embedded in a lipid bilayer. We carried out fluorescence pH
titrations to compare the behaviors of D2 and wt peptides at pH values lower than 3.5
(Fig. S3). While no fluorescence change was detected for wt at acidic pH values, we
observed that an additional process was present for D2 (with an apparent pKa of 2.5),
characterized by a fluorescence decrease and a redshift of the spectral maximum,
which might be associated with peptide exit from the lipid bilayer.

To establish the orientation of each helix in the membrane, we performed oriented
circular dichroism (OCD) measurements in which the light beam is oriented
perpendicular to the planes of a stack of oriented lipid bilayers containing the peptides
of interest. Theoretical calculations and experimental data indicate that helices
oriented with axes parallel with the membrane surface (perpendicular to the incident
light) give CD signals distinctly different from those of helices oriented across the
bilayer (parallel with the incident light).12,

13 and 14

In the range of 190–240 nm, the

peptide CD spectrum is dominated by π–π* and n–π* transitions.15 The π–π* transition
in a helix splits into three components, one of which gives rise to a negative Gaussian
band near 205 nm, with its electric transition dipole parallel with the helical axis.
When the incident light propagates parallel with the helical axis, the electric field
vector is orthogonal to the 205-nm π–π* dipole transition, and there is no interaction
between the electromagnetic wave and the dipole, leading to the disappearance of the
negative band at 205 nm in a CD spectrum. Thus, when the supported bilayers are
oriented perpendicular to the light propagation, a helix with a TM orientation will
have a CD spectrum that contains a positive 190-nm band and a negative 225-nm
band. If the helix adopts a membrane surface orientation on the supported bilayer, then
10

all transitions are seen, and the OCD spectrum is the same as for a peptide CD
spectrum in solution, with randomly oriented helices. Our data clearly indicate that D2
adopts a TM orientation at pH 3.5–4.5, while increasing the pH leads to peptide exit
and the appearance of a membrane surface orientation of the helix (Fig. 4). The OCD
spectrum at pH 1.9 does not correspond to a TM helix. Thus, we conclude that the pKa
of both or at least one of the His residues is significantly shifted from 6.3–6.916 to a
lower value (2.5) due to their location at the bilayer interface in state II, emphasizing
the important influence of bilayer surface properties on the pK values of dissociating
groups in interacting peptides. A similar trend was previously observed for peptides
that insert into membranes via the deprotonation of His residues,

17 and 18

although the

magnitude of the pKa shift was smaller. However, large changes in pKa are typically
observed when the side chains are in different environments, as the protonation of
titratable amino acids depends on the dielectric properties of their environment.19 A
fitting example of large pKa changes is found in the native environment of pHLIP,
bacteriorhodopsin, where Asp14 and Asp25 have pKa values of 7.5 and > 9,
respectively,20 significantly higher than the pKa values of 3.7–4.0 found for fully
solvated aspartic acid side chains.16

D1 has one less Asp residue at the C-terminus than D2. The slightly larger blueshift of
fluorescence emission (Fig. 2) and the higher content of helicity observed in the
presence of POPC at neutral pH values (Fig. 3) could be associated with an even
deeper position of the peptide in the membrane. Fluorescence spectral blueshift and
intensity increase, together with an increase in ellipticity at 222 nm, occur upon
acidification; this might indicate protonation of Asp33, Glu34, and the C-terminus, as
11

well as peptide insertion into the lipid bilayer. The OCD spectrum obtained for D1 at
pH 3.3 (Fig. 4) does not show a clear TM orientation of the helix: some decrease in
ellipticity at 205–225 nm—which might indicate the existence of a mixture of TM and
surface-parallel orientations of helices or the appearance of a significantly tilted TM
helix—is observed. D0, in contrast to all other pHLIP variants described above, has a
blueshifted maximum of fluorescence emission (Fig. 2) at neutral pH values in the
presence of POPC, with a high content of helical structure (Fig. 3). Virtually no
changes in spectral signal occur for D0 upon acidification (Figs. 2 and 3). The OCD
data primarily reveal a surface orientation of the helix at low pH values (Fig. 4), as
expected for a peptide with no aspartic acids.

To study the magnitude and directionality of the membrane insertion of the peptides,
we used a biotin–avidin binding assay. A biotin moiety was attached to the C-terminus
of each peptide. The level of binding to avidin was measured, and the protection of the
biotin molecule from avidin interaction was used to assess the translocation of the
peptide C-terminus into the liposome interior. The biotin moiety was linked to the Cterminal Cys of the peptides via a long polar polyethylene glycol (PEG) linker. The
linker has a double purpose. It facilitates biotin access to the avidin binding site and—
more critically for our experiments—helps to delineate between an intraliposomal
location and an extraliposomal location of the biotin, since the polarity of the moiety
makes a location inside the hydrophobic region of the bilayer unlikely. We quantified
the amount of biotin that binds to avidin molecules present exclusively outside the
liposomes (see Materials and Methods for details). We did not detect avidin binding to
biotin for the D2 peptide at low pH (Fig. 5a) due to the biotin translocation across the
12

membrane, which complements our data (suggesting complete insertion of this peptide
across the lipid bilayer) and confirms that the directionality of insertion is the same as
for wt. Only partial translocation and no translocation of biotin across the membrane
were seen for D1 and D0, respectively (Fig. 5a), in agreement with our results
indicating partial (or tilted) insertion and no insertion into the lipid bilayer of D1 and
D0, respectively. Additionally, the translocation of biotin (which can be considered as
a cargo) across the membrane does not appear to significantly hinder the membrane
insertion of the peptides. This might be explained by its small size (526 Da) and its
moderate polarity (logP = − 1.4; see Materials and Methods for details), which are
both well within the range of cargo properties that pHLIP has been reported to
effectively translocate.21 However, as the biotin assay used here is responsive to
changes in the level of binding to avidin present outside of the liposomes, we cannot
rule out the possible influences of different processes such as peptide aggregation,
although we have no reason to suspect them.

How does the number of carboxyl groups affect the pK and cooperativity of insertion?
We monitored the pH-induced changes in the position of the fluorescence emission
maximum of the peptides, which provide details about peptide insertion into the lipid
bilayer, in the presence of POPC (Fig. 6). A plot of the positions of the spectral
maxima follows a sigmoid behavior as a function of pH, corresponding to the
transition between the interfacial state and the inserted state for all variants (except for
D0). Fitting the experimental data provides the two main parameters that describe the
insertion process: pKa and cooperativity (m). The pKa of membrane insertion obtained
for wt pHLIP is 5.94 ± 0.09, which is in agreement with previous reports. 1 and 7 For the
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different variants, shifts of the pKa to lower values (∼ 5.2) were detected (Fig. 7a).
The reason for this decrease is unclear, but it might be related to the lower number of
aspartic residues or to the presence of histidines in the TM region of the pHLIP
variants. We do not think that the N-terminal DDDED sequence will influence the pKa
values of the peptides in our study, since its polarity should preclude hydrophobic
interaction with the lipid bilayer; thus, it is not expected to be involved in the insertion
process. However, we cannot rule out that it might reduce the overall membrane
affinity of the peptide. While the pKa values for the variants changed very little, we
observed a gradual decrease in the cooperativity of the insertion process (m
parameter) for peptides with fewer Asp residues, as the titration occurred
progressively over a wider pH range (∼ 1 pH unit for wt and ∼ 2 pH units for D1)
(Figs. 6 and 7b). Our data indicate that the cooperativity of insertion is linked to the
number of protonatable residues. Cooperativity and pKa might also respond to the
position of protonatable groups in the peptide sequences and their proximity to each
other. When pHLIP is at the surface of the vesicle and the pH is lowered, the
protonation of one Asp residue might facilitate the protonation of other protonatable
residues, shifting their pKa values. The protonation of the first Asp residue might
induce partial insertion of the peptide into the membrane. In this scenario, the
protonation of the neighboring Asp residues would be energetically favored to shield
the negative charge (i.e., the pKa value of the neighboring Asp is shifted to higher
values in a more hydrophobic environment) and then a positive feedback would be
established, triggering membrane insertion.

14

How do the number and the location of Asp residues affect peptide exit from the
membrane? The CD and fluorescence changes associated with wt pHLIP lipid
insertion at acidic pH are completely reversible.11 Here we also followed changes in
the CD and fluorescence signals and in the reversibility of biotin translocation across
the membrane. The ellipticity increase associated with each peptide insertion into the
membrane was found to be essentially reversible for wt and D3b (Fig. 3, broken blue
lines overlap with continuous blue lines), while for D3a, D2, and D1, the reversibility
was only partial. Since changes in the CD signal upon acidification for D2–D0 are less
pronounced than those for wt and D3, the reversibility of the D2–D0 membrane
insertion was also assessed by changes in the fluorescence signal (Fig. S4). It is
interesting to note the different levels of reversibility of the two D3 peptides: the
insertion process is significantly more reversible in D3b (90%) than in D3a (70%)
(Fig. 5b), suggesting nonequivalence of the two buried positions. We observed an
overall linear relationship between the number of aspartic acid residues interacting
with the membrane and the degree of α-helix formation reversibility (Fig. 5b). The
results obtained for the reversibility of the biotin translocation (exit process) were also
in agreement (Fig. 5b).

An important consideration in the interpretation of the exit data is the time course of
equilibration of the pH inside the liposomes, so we encapsulated the membraneimpermeable fluorescent probe 5(6)-carboxy-2′,7′-dichlorofluorescein in POPC
liposomes to follow the pH changes. The fluorescence of the probe is pH-sensitive,
with a pKa of 5.1. When we varied the pH of the solution outside the liposomes, the
fluorescence of the encapsulated probe changed in a sigmoid fashion, with an apparent
15

pKa of 5.05 (data not shown). A relatively high proton permeation through unilamellar
POPC liposomes in the minute timescale has been reported elsewhere.

22 and 23

On the

other hand, our kinetic data suggest that the time of wt peptide exit (with two TM
groups and four C-terminal protonatable groups) is in the range of milliseconds.6
Thus, peptides exit from the lipid bilayer much faster such that the pH is completely
equilibrated inside the liposomes and, most probably, C-terminal residues cross the
membrane in their noncharged form. The question is: ‘Why is the reversibility of D3a,
D2, and, to some degree, D1 only partial?’ To provide an explanation, we take into
account the location of the Asp residues. For the peptide exit from the lipid bilayer to
take place, the deprotonation of Asp residues must energetically destabilize the
inserted state. Destabilization of the inserted state is mainly caused by the charges
resulting from the deprotonation of groups deeply buried in the hydrophobic core of
the membrane. Therefore, the exit of wt and D3b, which have two Asp or one Asp in
the hydrophobic core of the membrane, is fully reversible. The reason for the
difference in peptide insertion reversibility between D3a and D3b might be related to
the presence of an arginine residue at position 11. Accordingly, the deprotonation of
Asp25 in D3b would strongly destabilize the membrane-inserted state due to the
presence of a negative charge in the hydrophobic core of the membrane, favoring the
exit process. However, the negative charge of Asp14 in D3a might be forming a salt
bridge with the neighboring side chain of Arg11, which would result in a weaker
destabilization of the inserted state. Another potential explanation is an altered
position of the TM domain, which was mentioned above. There is a possibility that the
TM domain in variants is shifted toward the C-terminal residues, leading to a greater
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exposure of the amino acid in position 14 (with His in D3a) to the aqueous
environment and a shift to the hydrophobic core of amino acids at positions 31 and 33.
As a result, the deprotonation of His14 in D3a might be associated with less
destabilization of the helix than deprotonation of His25 in D3b. The side chains of
Asp31 and Asp33 most probably are interacting with the headgroup region of the
bilayer. The destabilization energy associated with their deprotonation is not enough
to cause a complete exit from the membrane. Our results suggest that the
deprotonation of acidic residues located in the hydrophobic core of the membrane
ensures complete exit of the peptide.

Discussion
We have previously observed that even conservative changes in the pHLIP sequence
can lead to peptide aggregation in solution at neutral pH.7 Our results show that all the
peptides in this study are soluble in solution, being essentially monomeric (the
addition of a D-tag at the N-terminus and the L26G mutation appear to favor peptide
solubility). Spectral data obtained with D3–D0 peptides indicate that the lower is the
number of negatively charged groups in the peptide sequence, the deeper are the
peptide partitions into a lipid bilayer and the greater is the helicity. At the same time,
TM orientation (at least for the D3–D2 peptides) requires protonation of the Asp/Glu
residues and the terminal carboxyl group at the C-terminus, which can readily go
across a membrane in its noncharged form. We confirmed our previous finding2
suggesting that TM Asp residues are not essential for peptide insertion. Interestingly,
we have observed here that membrane insertion upon acidification occurs in our
peptides in the presence of two His residues in the predicted TM region. Histidines
17

have been used in the past to drive the insertion of peptides into membranes at neutral
pH values.17 and 18 However, in these examples, acidic residues were completely absent
in the sequence. For the peptides described in this article, the establishment of states II
and III is driven by acidic residues. Since the protonated (charged) state of the side
chains of His14 and His25 in the hydrophobic core of the membrane would be
energetically very unfavorable, in the peptides, their pKa values are expected to shift to
lower values in the membrane-inserted state (favoring the unprotonated state). Further
acidification eventually causes their protonation, resulting in a strong destabilization
of the inserted TM helix and peptide exit. We cannot rule out that the diminished
membrane insertion of the D1 and D0 peptides might be influenced by the
hydrophobicity change concomitant to the Asp-to-Asn mutations at the C-terminus.
The free energy of membrane transfer of the Asn side chain is 0.42 kcal/mol, which is
a less favorable value than the free energy of transfer of the neutral state of Asp
(− 0.07 kcal/mol)5; thus, the membrane translocation of the C-terminus would be less
favorable. A similar effect might occur in the insertion reversibility of D1.

We conclude that protonation of negatively charged residues located in the TM or in
the C-terminal inserting end must occur in order to preserve the pH-dependent ability
of pHLIP to interact with the membrane. These residues act as switches for pHLIP
membrane insertion, as the negative charges of their side chains block membrane
insertion. Acidification causes the protonation of these side chains, resulting in an
increase in the overall hydrophobicity of the peptide, which leads to TM helix
formation, shielding the hydrophobic residues of pHLIP from water molecules. When
the pH is raised to near neutrality, the negatively charged state of the carboxyl groups
18

is again favored, decreasing the peptide hydrophobicity and resulting in exit from the
TM position. Peptide exit from the lipid bilayer is completed when deprotonation of
Asp/Glu residues located in the hydrophobic core of the membrane occurs and the TM
helix is destabilized.

The knowledge gained from our experiments can be used as a guide to improve the
imaging and therapeutic properties of pHLIP. For the specific case of tumor targeting,
the pHLIP insertion characteristics should be finely tuned to exploit the low
extracellular pH (pHe) of tumors. Tumor targeting by wt pHLIP conjugated to a Cu64–
1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid chelate for positron emission
tomography imaging correlates with the pHe of tumors, where the contrast index was
higher for LNCaP tumors (pHe 6.78 ± 0.29) than for PC-3 tumors (pHe 7.23 ± 0.1024).
Thus, pHLIP variants where Asp14/Asp25 were replaced by Glu, with a higher pKa
(pKa = 6.5),7 might be more effective for targeting tumors with higher pH e values. Our
present results suggest that the number of Asp residues in the TM region can also
modulate the pKa value. Thus, a peptide containing an extra Asp in the TM region
might have a higher pKa and might be directed to tumors more effectively. Another
important factor to be considered is the broadness of the pH transition of the peptide,
which is dictated by the cooperativity of the transition. On one hand, for the case
where the peptide pKa is lower than the tumor pHe but the transition is broad (m value
is low), a significant part of the pH transition could intercept the pH e value, resulting
in a significant pHLIP tumor insertion. However, such a scenario will also lead to
more accumulation in healthy tissue. Since it is usually desirable to have a high
tumor/organ ratio, an insertion transition of high cooperativity might be best. This
19

would ensure greater differentiation between the amount of inserted peptides and the
amount of noninserted peptides over a narrow range of pH values, favoring selective
tumor targeting, since the difference in pH between normal tissue and cancerous tissue
may be only 0.5–0.7 units. However, we must bear in mind that the measured pHe
provides an indication of the average acidity outside the cell for a given tumor and can
vary between different tumor regions. Furthermore, pHe may not reflect the precise pH
on the exterior surface of the cells, since the cells pump protons to the extracellular
medium and ΔpH will lead to proton accumulation at the membrane surface.25
Another feature that is expected to shift the equilibrium toward the membrane-inserted
form is the presence of Asp/Glu residues at the C-terminus of the peptide. After being
translocated across the plasma membrane into the cytoplasm, where the pH is neutral,
these groups would be deprotonated. Since the translocation of charges across
membranes is unfavorable, the inserted form would be stabilized.

pHLIP shows promise as a means of targeting cells in acidic tissues and delivering
agents for therapy and imaging. At the same time, we are learning more about the
binding and insertion of peptides at the membrane surface. Here we have shown that
variation in the positions and numbers of carboxyl group titrations modulates the pK
and cooperativity of insertion.
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Materials and methods
Peptide synthesis and assessment of monomeric state

Peptides

were

made

by

solid-phase

synthesis,

using

standard

9-

fluorenylmethyloxycarbonyl chemistry, at the W. M. Keck Foundation Biotechnology
Resource at Yale University (New Haven, CT) and were purified by reverse-phase
chromatography (C18 column, using a water/acetonitrile gradient in 0.01%
trifluoroacetic acid). Purity was checked by matrix-assisted laser desorption/ionization
time-of-flight

mass spectrometry. Peptides

were quantified by absorbance

spectroscopy using a molar extinction coefficient of 13,940 M− 1 cm− 1. Some peptides
contain a single Cys residue in the C-terminus and thus have the potential to form
intermolecular disulfide bonds, leading to the formation of dimers. To rule out the
possibility that this might occur under our experimental conditions, we ran HPLC on
peptide samples incubated (at room temperature for 3 h) at concentrations higher than
those used in our experiments and in the absence and in the presence of POPC. No
dimer band could be detected, and concentrations in the range of 0.1 mM peptide and
overnight incubation were required to detect a significant amount of dimer (∼ 10%).
The peptides described in Table 1 were used in the experiments, except for some
experiments with D2–D0, where a Cys-less version was employed (similar results
were obtained for both results; data not shown).

Analytical ultracentrifugation

Sedimentation velocity experiments were performed at 25 °C in a Beckman Optima
XL-I analytical centrifuge at 35,000 rpm. Peptides at a concentration of 7 μM were
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dissolved in 5 mM phosphate buffer (pH 8) after 1 h of incubation at room
temperature. Absorbance at 280 nm was used to monitor centrifugation, and analysis
was performed using SEDFIT.26

Liposome preparation

The required amount of chloroform-dissolved POPC (Avanti Polar Lipids) was placed
in a glass tube, dried with argon, and then held under vacuum overnight. The dried
film was resuspended in water or 10 mM phosphate buffer (pH 8) and vortexed.
Extrusion to make unilamellar vesicles was performed using a Mini-Extruder (Avanti
Polar Lipids), with Nuclepore polycarbonate membranes of 0.1 or 0.05 μm pore size
(Whatman). To obtain the final large unilamellar vesicles, we performed 15–25
extrusion steps, depending on the lipid concentration.

Fluorescence spectroscopy

Peptides were dissolved in 5 or 10 mM phosphate buffer (pH 8) and incubated with
POPC vesicles prepared in water, resulting in a molar lipid/peptide ratio of 250:1. The
incubation time with POPC liposomes varied from 90 min to 18 h. The pH of the
samples was adjusted with a 10 mM concentration of the buffers for the indicated pH
ranges (H3PO4, pH 1.0–3.5; sodium acetate, pH 3.5–5.5; Na2HPO4/NaH2PO4, pH 5.5–
8.0; sodium borate, pH 8.0–10.5) or by addition of concentrated HCl. The final
peptide concentration was varied from 1.5 to 5 μM in different experiments. Emission
spectra were measured in SLM-Aminco 8000C and PC2 ISS spectrofluorometers at
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room temperature (controlled temperature), with excitation at 295 nm. The appropriate
blanks were subtracted in all cases.

For determination of spectral maxima, we used the FCAT mode of the PFAST
software, which fits the experimental spectra to log-normal components.27 and 28 The
spectral maxima values for each point of the pH curve were plotted and analyzed
according to29:

F

F

 Fb 10 m ( pH  pKa)
(1  10 m ( pH  pKa) )
a



Equation(1)

where Fa = (fA + SApH) and Fb = (fB + SBpH); fA and fB are the spectral maxima for the
acidic and basic forms, respectively; SA and SB are the slopes of the acidic and basic
baselines, respectively; and m is the cooperativity parameter. Fitting by nonlinear least
squares analysis was carried out with Origin software.
Circular dichroism

Samples were prepared as in the fluorescence experiments, but the final molar
lipid/peptide ratio was 300:1, with the final peptide concentration varying from 2 to
5 μM. CD spectra were recorded in Jasco J-810 and MOS450 Biologic
spectropolarimeters interfaced with a Peltier system. Spectra were recorded at 25 °C
using 2- or 5-mm cuvettes, the scan rate was 50 nm/min, and 10–30 averaging steps
were performed. Raw data were converted into mean residue ellipticity according to30:
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[Θ]=Θ/(10lcN)
where Θ is the measured ellipticity, l is the path length of the cell, c is the protein
concentration, and N is the number of amino acids.

For the study of membrane attachment, insertion, and its reversibility, the typical
procedure was as follows: The samples were incubated with POPC vesicles at pH 8
for 90 min, the spectra were recorded, the pH was lowered to 4.0, and the
measurements were performed after 30 min. Finally, the pH of the sample was
increased with sodium borate buffer (pH 10.2) to a final pH of 7.5. After 30 min,
90 min, and 24 h, the spectra were recorded, and similar results were obtained in all
cases. The degree of reversibility was established from the recovery of the signal at
222 nm. The final buffer concentration for the different experiments was in the range
of 3–15 mM. Appropriate blanks were subtracted in all cases.

OCD measurements

For OCD measurements, supported bilayers were prepared on quartz slides with 0.2mm-thick spacers on one side and with a special polish for far-UV measurements
(Starna). Slides were cleaned by sonication for 10 min in cuvette cleaner solution
(Decon Contrad 70, 5% in water), 2-propanol, acetone, and 2-propanol, and rinsed
with deionized water. Then the slides were immersed in a mixture of concentrated
sulfuric acid and hydrogen peroxide (3:1) for 5–10 min to completely remove any
remaining organic material from the slides. The slides were then thoroughly rinsed
with and stored in deionized water (Milli-Q purified water kept at 25 °C). A POPC
lipid monolayer was deposited on a quartz substrate by the Langmuir–Blodgett
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method using a KSV mini-trough. For the Langmuir–Blodgett deposition, a cleaned
slide was vertically immersed in the clean subphase (Milli-Q purified water kept at
25 °C) of a Langmuir–Blodgett trough. A POPC lipid solution in chloroform was
spread on the subphase, and chloroform was allowed to evaporate for about 30 min,
followed by monolayer compression to 32 mN/m. The first layer was deposited by
retrieving the slide from the subphase at a rate of 15 mm/min. The second layer of the
bilayer was created by fusion. For this step, the monolayer on the slide was incubated
with a solution of POPC vesicles (50 nm in diameter, obtained by extrusion) mixed
with peptide solution at the required pH (0.5 mM POPC and 10 μM peptide). The
fusion occurred for about 6 h under 100% humidity. Then, excess vesicles were
carefully removed, and the slides were stacked to make a pile while filling up the
spaces between them with a peptide solution (5 μM) at the required pH. The bilayers
with the peptide solution were allowed to equilibrate for about 6 h. Measurements
were taken in three steps during the process: when the monolayers were incubated
with an excess of liposomes, soon after the spaces between the bilayers had been filled
with the peptide solution and 6 h after the second measurement. Fourteen slides (28
bilayers) were assembled, and the OCD spectrum was recorded on a MOS-450
spectrometer at a sampling time of 2 s.

Biotin translocation assay
HABA dye (4′-hydroxyazobenzene-2-carboxylic acid) binds to avidin at a 1:1
stoichiometry and absorbs at 510 nm only in the avidin-bound state. This interaction is
strongly displaced by the binding of biotin to avidin, resulting in a quantitative
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reduction in HABA absorbance. This property was used to probe the location of the Cterminus of different peptides with regard to the liposome (inside or outside) (method
modified from Nicol et al.31). The C-terminus of each of the peptide variants was
labeled with biotin (see the text below). The rationale for the assay is that pH-driven
insertion of the C-terminus would result in biotin translocation inside the liposome,
causing shielding of the biotin from the medium outside the liposome, where a
preformed HABA/avidin complex (Thermo Scientific) is added. If the biotin is inside
the liposome, no change in absorbance is expected. On the other hand, if pHLIP lies at
the exterior surface of the liposome, the C-terminal biotin would be accessible to the
solution outside the liposome (as the biotin group is polar, it is expected not to be
protected by the membrane) and would be able to bind to avidin and displace the
HABA/avidin complex, with a consequent reduction in absorbance at 510 nm.
Liposomes were prepared in 150 mM NaCl, and ionic strength was carefully
maintained during all steps to avoid liposome osmotic shock. Biotin-labeled peptides
were incubated in the presence of POPC at pH 8 for 2 h at room temperature (150:1
lipid/peptide ratio). For studies of C-terminal translocation, acetate buffer was added
to the samples, resulting in a final pH of 4.3 prior to 1 h of incubation with the
peptide. The HABA/avidin complex was added to the solution only after the final
conditions had been established. The final peptide concentration for the measurement
conditions was 3 μM. To determine the reversibility of the biotin translocation, we
increased the pH by the addition of 10 mM sodium borate buffer (pH 10.2) to give a
final pH of 7.4. Absorbance was measured after 1 h of incubation. For quantitation of
the level of reversibility, the recovery of absorbance obtained for pHLIP labeled with
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biotin at its C-terminus was taken as 100% reversibility, and that of pHLIP labeled at
its N-terminus was taken as 0%.

Peptides were labeled at the C-terminal Cys residues using the membraneimpermeable compound maleimide–PEG2–biotin (Thermo Scientific), which has a
long polar spacer arm of 29.1 Å to allow adequate biotin binding to avidin. The
synthesis reaction was performed in 10 mM phosphate buffer (pH 7.5; overnight
incubation at 4 °C). Reaction products were purified by HPLC, and the mass of the
biotin-labeled peptides was checked by matrix-assisted laser desorption/ionization
time-of-flight mass spectrometry. The octanol/water partition coefficient of
maleimide–PEG2–biotin was determined experimentally by measuring the absorbance
at 300 nm in the aqueous and octanol (previously preequilibrated with water) phases
after 2 h of vortexing. A logP value of − 1.07 ± 0.02 was obtained. As this value does
not take into account the chemical changes in the cross-linking reaction (formation of
a thioether bond between the maleimide moiety and the Cys side chain), the QikProp
3.0 software was employed to predict the logP value of the reacted form, resulting in a
value of − 1.4, which is in the range of molecules that can be translocated by pHLIP.21
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Tables

Table 1. Sequence of the peptides.
wta
D3ab
D3b
D2c
D1c
D0c

AAEQNPIYWARYADWLFTTPLLLLDLALLVDADEGTCG
DDDEDNPIYWARYADWLFTTPLLLLHGALLVDADECT
DDDEDNPIYWARYAHWLFTTPLLLLDGALLVDADECT
DDDEDNPIYWARYAHWLFTTPLLLLHGALLVDADECT
DDDEDNPIYWARYAHWLFTTPLLLLHGALLVNADECT
DDDEDNPIYWARYAHWLFTTPLLLLHGALLVNANECT
14

a

b

25

31 33

The pHLIP sequence is referred to as wt.
The variant peptides are named by a D followed by the number of aspartic acid

residues in the TM and C-terminal regions. Two different D3 peptides were studied,
D3a and D3b, each with different transmembrane aspartic acid residues mutated. The
acidic residues that are expected to interact with the hydrophobic core of the
membrane at some stage of the insertion process (Asp 14, 25, 31 and 33, in red) were
mutated to the polar residues marked in bold. The N-terminal Asp-tag and the
Leu26Gly mutation are highlighted in italics. The transmembrane region of pHLIP
was predicted, using the octanol scale5, to be located between residues Ile7 and Leu29
(marked with inverted blue triangles). N- and C-terminus were not capped.
c

A version of D2-D0 without cysteine were employed in experiments except of biotin

translocation assay.
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Table 2. Parameters describing the studied peptides.
AUC a
Sed.
Coef.
State
I
wt
D3a
D3b
D2
D1
D0

0.80±0.17b
0.67±0.08
0.66±0.09
0.84±0.16
0.88±0.18
0.75±0.20

Fluorescence
Spectral maximum, nm

I

State
II

III

347.7±0.6
349.9±0.1
349.1±1.0
348.2±0.1
346.2±3.6
347.2±1.0

347.2±1.6
347.4±1.3
345.5±0.7
344.9±1.4
343.7±1.6
341.0±0.6

336.7±0.1
337.0±0.1
334.6±0.2
336.5±0.7
337.4±1.0
338.0±0.9

Circular
Dichroism
Area
curve
State
II
III
1.04
1.12
1.08
1.09
1.10
1.71

2.10
2.61
2.11
1.53
1.46
1.21

MRE 218 nm

I
-7.4
-7.6
-5.3
-7.9
-7.0
-6.5

State
II
III
-7.4
-6.8
-6.1
-9.3
-10.5
-13.5

-16.3
-15.4
-16.4
-14.1
-15.6
-12.8

a

The sedimentation coefficient for the peak corresponding to the monomer is showed.

b

The averages and the standard deviations are provided.

c

The spectral maxima were calculated with PFAST (see Methods).
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Figures

Figure 1. Sedimentation velocity of the different peptide variants. Apparent
sedimentation coefficient distribution derived from sedimentation velocity profiles of
the peptides(7 µM)) in 5 mM phosphate buffer at pH 8.
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Figure 2. Fluorescence spectra of peptides in buffer and with POPC vesicles.
Emission spectra of each variant were recorded under the following conditions: buffer
at pH 7.5 (black lines), POPC at neutral pH (blue lines), and POPC at pH 4 (red lines).
The pH values for the different POPC samples at neutral pH were selected according
to the midpoint and slope of the transitions shown in Figure 6: wt, pH 7.5; D3a,
pH 7.5; D3b, pH 7.1; D2, pH 6.5; D1, pH 6.2; D0, pH 8. The peptide concentration
was 1.5 μM, and the lipid concentration was 375 μM. Fluorescence intensity is given
in arbitrary units (AU).
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Figure 3. CD of peptides in buffer and with POPC vesicles. Far-UV CD spectra
were recorded for all variants under different conditions: buffer at pH 7.5 (black lines),
POPC at pH 7.4 (blue lines), and POPC at pH 4 (red lines). The reversibility of the
insertion process was studied by raising the pH of the samples from pH 4 (broken blue
line) to pH 7.4. Reversibility for D0 was not studied, as the ellipticity changes between
the states at pH 7.5 and pH 4 were negligible. In all samples, the final peptide and
lipid concentrations were 5 μM and 1.5 mM, respectively.
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Figure 4. OCD spectra of D2, D1, and D0 measured on oriented POPC-supported
bilayers at neutral (blue lines) and acidic (red lines) pH values. The OCD spectrum
of D2 at pH 1.9 was also recorded (purple line). The experimental spectra are
corrected for the lipid background.
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Figure 5. Quantification of membrane insertion (biotin translocation) and
reversibility. Data corresponding to the biotin translocation assay (open squares) and
CD (black symbols) were plotted against the number of Asp residues in the TM and Cterminal regions. (a) Degree of normalized biotin translocation (open squares). For
data normalization, the translocation levels of wt pHLIP labeled with biotin at the Cterminus and N-terminus were used as 100% and 0%, respectively. Results from D3a
and D3b are not shown for the biotin translocation assay, as the biotin labeling for
these peptides affected the interaction with lipids (data not shown). No adverse effects
of labeling were observed for the rest of the peptides tested. Averages and standard
deviations are shown. (b) The percent reversibility of the biotin translocation of the
samples used in (a) is shown (open squares). For CD experiments (Fig. 3), the degree
of reversibility was determined by monitoring the relative changes in ellipticity at
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222 nm (black symbols). Averages and standard deviations are shown. Data
corresponding to D3b appear as a triangle, while the rest of the CD data appear as
circles. All data points were used for linear fitting (R2 = 0.95).
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Figure 6. Fluorescence spectral maximum changes upon pH titration. The pHcontrolled transitions of the peptides in POPC were followed by monitoring the
variations in the spectral maxima. The experimental data for the different peptides
were fitted to Eq. (1) (black lines). Representative experiments are shown.
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Figure 7. Parameters obtained from the fitting of fluorescence pH transitions.
The pKa (a) and m parameter (b) values obtained from the fitting of the data in Figure
6 to Eq. (1) are shown in black symbols. Data from the D3b variant are shown as
triangles (to maintain the representation as in Fig. 5). The line corresponds to the
fitting of all data points (R2 = 0.93). Averages and standard deviations are shown.
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Supplementary information
Roles of carboxyl groups in the transmembrane insertion of peptides.
Francisco N. Barrera, Dhammika Weerakkody, Michael Anderson, Oleg A. Andreev,
Yana K. Reshetnyak and Donald M. Engelman

Figure S1. Fluorescence of D2 in presence of POPC at various pH values.
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Figure S2. Leakage of encapsulated calcein. The release of calcein encapsulated in
large unilamellar POPC liposomes was measured by following the fluorescence at 515
nm in the presence of different concentrations of peptides. Little disruption by peptide
interaction is seen. The level of 100% disruption of liposomes was determined by
addition of 0.05% Triton X-100
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Figure S3.

Fluorescence of wt and D2 at low pHs. The usual range of pHs was

extended to lower values to study the protonation state of His residues. D2 was
employed as an example of peptide containing two His residues. Upper panels:
Emission spectra in POPC liposomes at pH 2.2, 3.3 and 6.3. Lower panels: the
fluorescence intensity and center of mass were calculated for the complete pH range
studied for D2 and wt pHLIP.
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Figure S4.

Fluorescence studies of the reversibility of the membrane insertion

for D2, D1 and D0. Spectra were measured of the peptides in the presence of POPC at
pH 4.1 (red lines) and 7.8 (straight blue lines). The pH of the samples at pH 4.1 was
increased back to 7.8 (dashed blue lines) to study reversibility. For D2, where
acidification caused TM helix formation occurs, the two blue lines have a good
overlap, suggesting a high degree of reversibility. For D1 and D0, a TM helix is not
formed in a pH-dependent fashion, so the interpretation of the reversibility data is less
straightforward.
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Abstract
Solid tumors are inherently acidic, with more aggressive growth producing
greater acidity. If the acidity could be targeted as a biomarker, it would provide a
means to gauge the pace of tumor growth and degree of invasiveness as well as
providing a basis for predicting responses to pH-dependent chemotherapies. We have
developed a new

64

Cu-pHLIP peptide for targeting, imaging and quantifying acidic

tumors by positron emission tomography, and our findings reveal utility in assessing
prostate tumors. The new pHLIP version limits indiscriminate healthy tissue binding,
and we demonstrate its targeting of extracellular acidification in three different
prostate cancer models, each with different vascularization and acid-extruding protein
carbonic anhydrase IX (CAIX) expression. We then describe the tumor distribution of
this radiotracer ex vivo, in association with blood perfusion and known biomarkers of
acidity such as hypoxia, lactate dehydrogenase A and CAIX. We find that the new
probe reveals metabolic variations between and within tumors, and discriminates
between necrotic and living tumor areas.
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Introduction
The rapid growth and division of tumor cells creates an enhanced need for
glucose and other nutrients, which the cells take up at a high rate, overwhelming their
mitochondrial capacity to use all of the glucose efficiently (1). The result is aerobic
glycolysis, which elevates lactate and proton production: the “Warburg” effect (1, 2).
Further, some tumors are starved for oxygen, resulting in even more glycolytic acid
production (3, 4). Under the resulting low pH conditions, normal cells have a tendency
to undergo p53-induced apoptosis (5, 6), whereas cancerous cells invoke alternative
routes, manipulating ion fluxes with proton extruders and other transporters to afford
continuous survival (7). Pumping the acidic components out of the cell maintains
cytoplasmic pH and enhances the pH gradient (ΔpH) and the cellular exterior surfaces
become more acidic than those of cells in normal tissues (8). The level of extracellular
acidification, however, is variable, depending on (i) the reliance of the malignancy on
glycolysis (9-12), a phenomenon resulting from the pleiotropic adaptation of cancer
cells towards a glycolytic phenotype, (ii) the impact of variation in the distal vascular
delivery of nutrients, and (iii) the state of hypoxia (13, 14). The low pH environment
stimulates cell invasion, angiogenesis and finally, metastasis (15-17).
Tumor acidosis could be a useful biomarker for selective drug delivery,
targeting and delineation of malignancies. With the discovery of a membrane-inserting
peptide (pHLIP) that preferentially binds to cell membranes at low pH, practical
clinical imaging and delivery of therapeutic payloads may be possible (18-22). At
normal pH, pHLIP binds as a largely unstructured peptide at a membrane surface, but
at acidic pH it folds and inserts across the plasma membrane as an alpha helix (23).
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We have previously demonstrated that pHLIP might be useful as a PET (Positron
Emission Tomography) probe with

64

Cu (t1/2~12.7 h) (24). Tumor uptake in prostate

cancer models was achieved, and related to a low extracellular pH (pHe), but
shortcomings were apparent (24). The success of the probe as a marker of acidosis was
found

to

have

contrast

and

clearance

complexities

associated

with

the

pharmacokinetics (PK) of pHLIP, warranting further development efforts. Targeting
of fluorescent pHLIP variants were recently studied, and a range of potential
properties was found, including altered kinetics of insertion (Scheme 1) (25). Here, we
describe a much improved PET probe that was developed using three strategies:
modification of the 1) peptide sequence, 2) radiometal and 3) chelate. We confirmed
the lead radiotracer’s specificity for a low pH gradient by demonstrating an
association between pHLIP-PET and pHe in different prostate cancer models, i) PC3wt, ii) the constitutively expressing carbonic anhydrase IX-transduced PC3 (PC3CAIX) and, iii) LNCaP cancer cells. Lastly, we extended our study by offering a
representative relationship of pHLIP with perfusion, tumor viability and pathways
associated with acidity (i.e. lactate via the lactate dehydrogenase A (LDH-A) protein
subunit, hypoxia and CAIX overexpression). The new probe gives useful contrast,
reveals metabolic variations within tumors and discriminates between necrotic and
living tumor areas.

Name
pHLIP-WT

Scheme 1. pHLIP variants and their sequence
Sequence
ACEQNPIYWARYADWLFTTPLLLLDLALLVDADEGT

Var1

ACEDQNPYWARYADWLFTTPLLLLDLALLVDG

Var2

ACEDQNPYWRAYADLFTPLTLLDLLALWDG

Var12

ACEDQNPWARYADLLFPTTLAW

Var13

ACEEQNPWARYAELLFPTTLAW
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Var10

ACEDQNPWARYADWLFPTTLLLLD

Var11

ACEEQNPWARYAEWLFPTTLLLLE

Var7

ACEEQNPWARYLEWLFPTETLLLEL

Var5

ACDDQNPWRAYLDLLFPTDTLLLDLLW

K-WT (control)

ACEQNPIYWARYAKWLFTTPLLLLKLALLVDADEGT

Results
Appropriate peptide sequence, radionuclide and chelating ligand modifications
can significantly improve pHLIP-PET properties.
In Vitro Studies. We made several modifications to reduce the non-specific binding of
the PET probe to normal tissues in order to maximize contrast while maintaining
tumor specificity.

Based on reports revealing that simple replacement of a

radionuclide can significantly alter the PK characteristics of a PET probe (26-28), we
labeled WT and truncated versions of pHLIP from Scheme 1 with 68Ga (t1/2 ~ 68 min)
in lieu of 64Cu (t1/2 ~ 12.7 h). Variants of pHLIP were conjugated with DOTA via a
thioether linkage made via a nucleophilic reaction between the maleimide side chain
of the macrocycle and the thiol functional group of a cysteine in pHLIP.

68

Ga-

radiolabeling of these variants was facilitated via a microwave-assisted reaction at 90
C for 1 min at pH~5.5. Assays performed in vitro were used to identify our lead
pHLIP variant for studies in vivo. Measurements of the octanol/water partition
coefficient (Log P) showed that, among the pHLIP variants tested, 68Ga-DOTA-WT is
the most hydrophilic (Log P ~ -2.26 ± 0.04) while

68

Ga-DOTA-Var7 is the most

hydrophobic (Log P ~ -1.10 ± 0.05) (Table 1). Binding assays using PC3-wt prostate
cancer cells in different pH-buffered environments (pH~ 6.3, 6.7, 7.0) showed that
these peptides target cells at low pH. The binding activity of each radiolabeled pHLIP
variant, expressed as “% Bound” normalized to the added amount of probe, is
51

displayed in Fig. 1. Variants WT and Var7 were selected as lead compounds for small
animal PET imaging and biodistribution studies in vivo, due to their differential but
favorable binding at low pH and significantly lower uptake at neutral pH, resulting in
an improved dynamic range/contrast in the pH range of interest (pH 6 - 7.4). The
control peptide, K-WT, showed a reverse trend, with enhanced binding at high pH.
The lysine residues in K-WT are in their charged form at low pH, inhibiting
membrane insertion, while in a more alkaline environment these lysine residues may
be partially protonated, enhancing peptide-membrane interaction (29).
68

Ga-DOTA-WT vs.

68

Ga-DOTA-Var7. Encouraged by the results of our assays in

vitro, we conducted in vivo experiments with subcutaneous (s.c.) PC3-wt prostate
tumor xenografts. Serial PET images acquired (SI Fig. 1) at 1-4 h post-injection (p.i.)
of 68Ga-DOTA-WT demonstrate non-specific tissue binding of the probe, resulting in
poor contrast visualization of the tumors implanted on the shoulder. Ex vivo tissue
biodistribution analysis was conducted to measure the amount of probe bound to
tumor and normal tissues at 1 h, 2 h, and 4 h p.i. to parallel the kinetics observed in the
PET images. These data (SI Table 1) showed tumor uptake, expressed as % of
injected dose per gram of tissue (%ID/g) at 1 h (1.87 ± 0.45 %ID/g), 2 h (2.36 ± 0.40
%ID/g) and 4 h (2.86 ± 0.75 %ID/g), in good agreement with previously reported data
using
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Cu, demonstrating probe affinity for the tumor (24). However, non-specific

binding of

68

Ga-DOTA-WT to normal tissues observed in the biodistribution results

(Fig. 2A, SI Table 1) even at 4 h p.i. explains the poor contrast seen in the PET
images (SI Fig. 1). For example, tumor-to-healthy tissue ratios versus muscle (2.02 ±
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1.97), blood (0.43 ± 0.16), liver (0.40 ± 0.05) and kidneys (0.37 ± 0.16) at 4 h p.i.
were poor, necessitating further improvement (Table 2).
The shorter

68

Ga-DOTA-Var7 variant was examined in the same PC3-wt

tumor model using similar methods of preparation. Compared to the WT sequence,
68

Ga-DOTA-Var7 exhibited significantly improved properties. From the tissue

distribution (SI Table 2), the probe accumulation within the tumor progressed from
2.47 ± 0.19 %ID/g at 1 h to finally, 5.60 ± 0.30 %ID/g at 4 h p.i. The acquired PET
images further reflected the observed tissue distribution (SI Fig. 2).
A direct comparative analysis between the two

68

Ga-labeled probes

demonstrated a higher tumor uptake with the shorter sequence compared to the parent
WT. The blood residence at 4 h p.i. was similar; however, slightly increased nonspecific tissue binding was demonstrated by

68

Ga-DOTA-Var7 (Fig. 2A). Compared

to the WT peptide, the kidney uptake for Var7 was elevated, which can be rationalized
as resulting from faster probe clearance. Comparing tumor-to-background ratios of
both radiotracers in Table 2, an overall increase in contrast with Var7 is seen. Based
on these observations, Var7 was chosen as the lead pHLIP variant for further
preclinical evaluation.

DOTA vs. NOTA. Even with shorter variants, the residence time of pHLIP appears
longer than the physical half-life of

68

Ga, so we reconsidered using

match the biological half-life of pHLIP.
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conducted using methods similar to that of

64

Cu to better

Cu radiolabeling of DOTA-Var7 was
68

Ga labeling. Ex vivo biodistribution

results (SI Table 3) using PC3-wt tumor-bearing mice displayed tumor uptake at 1 h
p.i. (1.19 ± 0.55 %ID/g), and significant retention after 24 h (1.64 ± 0.38 %ID/g, Fig.
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2B). The blood residence activity improved with a final tumor-to-blood ratio of 2.63 ±
0.57 at 24 h p.i. (Table 3). Despite improvements made on the pHLIP backbone,
concerns still remained with radiotracer retention in key organs. Hepatic uptake of the
radiotracer displayed unremarkable retention over 24 h with 6.05 ± 1.36 %ID/g (Fig.
2B-C), similar to the values reported for the

64

Cu-DOTA-WT construct (4.88 ± 0.98

%ID/g at 24 h) (24); this uptake is likely to be from random scavenging of radioactive
metabolites, including de-metallated 64Cu in the liver (30, 31). The tracer distribution
in the kidney revealed only nominal reduction, even after 24 h (19.6 ± 4.0 %ID/g),
likely due to the renal acidic environment (pH~5), which is expected to cause binding
of these pHLIP variants for a period of time (32), but possibly including other effects,
since it could be improved (see below).
Our efforts to limit indiscriminate tissue accretion of pHLIP PET probes led us
to seek improvements of the radiometal-chelate stability and the resistance to
proteolytic degradation. Var7 was modified with the NOTA ligand. In addition, since
previous reports described superior chelate affinity for

64

Cu (33-35) and, in addition,

we employed D-amino acids (named Var7(D) from now on), known for resistance to
enzymatic proteolysis compared to L-peptidomimetics (36-38). Similar

64

Cu

radiolabeling conditions were employed as described above. In PC3-wt xenografts, no
differences in tumor accretion were seen between

64

Cu-NOTA-Var7(D) (Fig. 2B, SI

Table 4) and the DOTA scaffold (Fig. 2B, SI Table 3).
The design changes in

64

Cu-NOTA-Var7(D) resulted in significant improvements of

several properties. First, renal accumulation showed a greatly improved, exponential
clearance from 13.27 ± 0.65 %ID/g (1 h) to 5.84 ± 0.89 %ID/g (4 h) and finally, 3.86
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± 1.14 %ID/g (24 h). Second, a new route of clearance - via the intestinal organs - was
found (SI Table 4). Third, negligible hepatic radiotracer retention was seen at 24 h
(0.88 ± 0.26 %ID/g, Fig. 2B). Finally, the significant clearance of

64

Cu-NOTA-

Var7(D) from healthy tissues gave clear visualization of tumors as tumor-to-tissue
contrasts (Table 3) progressed over 24 h, for example, against blood (0.81 ± 0.22),
muscle (7.81 ± 0.88), liver (1.56 ± 0.40), small intestines (3.7 ± 1.0) and kidneys (0.39
± 0.17).
PET images using

64

Cu-NOTA-Var7(D) acquired on mice implanted with

bilateral s.c. PC3-wt (right shoulder) and LNCaP (left shoulder) xenografts exhibited
promising PK properties (Fig. 2D, left) with progressive clearance of the tracer from
the liver, muscle, gut and kidneys over 24 h, which were key problem areas with
previous pHLIP PET probes.
Biophysical characterization of 64Cu-NOTA-Var7(D), our lead compound.
We tested the new compound, 64Cu-NOTA-Var7(D), for solubility and for the
pHLIP property of pH dependent insertion to form a transmembrane helix.
Sedimentation velocity measurements show that Cu-NOTA-Var7(D) forms a dimer in
aqueous solution at concentrations of 7-8 µM at high and neutral pHs, in contrast to
more aggregated forms of other Cu-pHLIP constructs (see SI Table 5 and SI Fig. 3).
The pH-dependent changes in circular dichroism (Fig. 3A) and tryptophan
fluorescence signals (Fig. 3B) are similar to those observed for the peptide with no
chelate and metal (25) indicating pH-dependent interaction of the pHLIP portion with
the membrane. The apparent pKa of insertion was ~ 5.9 (Fig. 3C), which is slightly
higher than for the peptide alone (5.5), probably due to the presence of the chelate.
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The log P value of
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Cu-NOTA-Var7(D) was measured as -2.45 ± 0.13, revealing a

significantly polar compound. The properties of increased solubility and the elevation
of the pK of insertion may contribute to its improved properties in vivo.
Probe accumulation correlates with acidity.
We wanted to explore disparities, if any, in the extacellular pH (pHe) of tumors
with and without pHe regulators, particularly in tumors transduced to overexpress
CAIX, a carbonic anhydrase elevated in tumor cells to cope with high CO2 production.
Thus, CAIX-transduced PC3 (PC3-CAIX) prostate cancer cells were established via
the transduction of PC3-wt cells with a newly developed retroviral vector SFG-CAIXIRES2-GFP. Via cell sorting, populations of GFP-expressing cells were collected (SI
Fig. 4A) and Western blots confirmed higher CAIX expression in PC3-CAIX than in
the wt cells under normal oxygen conditions (20 % O2) (SI Fig. 4B).
The intrinsic acidity of the three prostate xenografts (PC3-wt, PC3-CAIX and
LNCaP) was evaluated by measuring pHe and pHi (intracellular pH) via 1H-decoupled
31

P-MRS using 3-APP (Fig. 4A). Each of the three tumor models exhibited a lower

whole-tumor pHe (Fig. 4B) than its whole-tumor pHi (Fig. 4C), in concordance with
previous studies (39-42). Of all the tumor models, LNCaP tumors had the highest pHi
(7.28 ± 0.07) and pHe (7.07 ± 0.04) while the PC3-wt xenografts exhibited both the
lowest pHi (6.94 ± 0.07) and pHe (6.93 ± 0.03). In contrast to the wt model, the
CAIX-enhanced tumor implants displayed an alkaline-shifted pHi (7.26 ± 0.09, P =
0.012) and pHe (7.07 ± 0.06, P = 0.035). Analysis of the pH (pHi-pHe) of these
tumors revealed similar proton fluxes in LNCaP (0.27 ± 0.10, P = 0.020) and PC3-
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CAIX (0.33 ± 0.13, P = 0.018), establishing greater extracellular acidification
gradients in these two xenografts than in PC3-wt (-0.010 ± 0.055) (Fig. 4D).
Uptake of 64Cu-NOTA-Var7(D) correlates inversely with pHe when data from
all three tumor models are taken into account. Each mouse used for pH MRS
measurements was also used for PET and biodistribution experiments, giving greater
confidence in the correlations (for pairing details see SI Table 6). In the plot of pHe
versus

64

Cu-NOTA-Var7(D) uptake (PET imaging at 1 h p.i. and 24 h ex vivo tissue

sampling radioactivity assays) taken from the distribution studies (Fig. 5A),
incremental accumulation of the radiotracer is seen as the tumor acidity increases. By
pooling all data points from all prostate xenografts (Fig. 5B), threshold limits can be
established from the data, showing that a tumor pHe < 6.9 provides high probe
localization (> 3.0 %ID/g), whereas a pHe range of 6.9 – 7.4 results in lower probe
uptake (< 3.0 %ID/g).
Ex vivo autoradiography demonstrates pHLIP accumulation in tumor regions
associated with elevated metabolism
Histological staining was used to examine viability and metabolic features of
the tissues that stain or do not stain with the probe. Figures 6A-C shows the
distribution of

64

Cu-NOTA-Var7(D) (autoradiography), and correlative histologic

markers pimonidazole (green, hypoxia), Hoechst 33342 (blue, vascular perfusion) and
lactate dehydrogenase A (LDH-A, red) in representative PC3-CAIX (top row), LNCaP
(middle row) and PC3-wt (bottom row) tumors. Histological stains (hematoxylin and
eosin) were also conducted to determine tumor tissue viability (SI Fig. 5). In all
tumors, the

64

Cu-NOTA-Var7(D) distribution is heterogeneous, with increasing
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accumulation seen in perinecrotic, hypoxic tumor regions. Binding of

64

Cu-NOTA-

Var7(D) is also observed in the animal skin, an inherent acidic tissue, indicated by the
red arrows on the tumor sections. Figures 6D-F contains re-binned scatterplots of the
relative pixel intensity values of the images shown in Fig. 6A-C respectively. In all
cases, the regions of highest

64

Cu-NOTA-Var7(D) uptake corresponded with regions

of highest pimonidazole and LDH-A staining, with the converse lowest

64

Cu-NOTA-

Var7(D) corresponding to the regions of lowest LDH-A expression and pimonidazole
uptake. There appeared to be no relationship between Hoechst 33342 staining intensity
and

64

Cu-NOTA-Var7(D) uptake. Thus, we find that probe uptake is correlated with

hypoxia and LDH-A.
Discussion
By creating a useful probe for imaging tumor acidosis, we enable assessment
of a universal trait associated with tumor invasiveness in most malignancies. We
illustrated the improvements made toward better PK and dosimetric properties of
pHLIP as a non-invasive PET radiotracer. More importantly, this probe was able to
distinguish highly acidic tumors, with a direct association to tumor pHe. Furthermore,
we extended our efforts to understanding the mechanism of uptake of this probe
through autoradiographic and histologic studies of all three tumor models to provide
insights on its target.
Based on a set of observations with earlier pHLIP-based probes, we were able
to design a new version that should prove useful in clinical applications. The Var7
variant sequence of pHLIP proved to offer faster clearance and tumor delivery than the
parent pHLIP; however, its prolonged residence in healthy tissue paired with the short
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physical half-life of

68

Ga was mismatched, and degradation of the peptide was

suspected. To cope with these we synthesized the peptide from D-amino acids and
revisited the use of

64

Cu, which has a longer half-life to allow clearance of the probe

from healthy tissue. The relatively poor chelating properties of DOTA for

64

Cu had

resulted in accumulation of unbound Cu in tissues (i.e. liver) (31), so we searched for
a better chelation group, deciding on NOTA. This set of design choices gave us 64CuNOTA-Var7(D). The superiority of NOTA to DOTA is clear in the comparisons of
biodistribution, tumor-to-tissue contrast ratios and PET imaging (Fig. 2C-D, SI
Tables 3-4). A much lower uptake is seen in the liver, intestines, spleen and kidneys,
resulting in improved contrast ratios between these tissues and the tumor. We now
have a workable probe to develop for clinical use.
Our results differ in some respects from those reported earlier. In our hands,
comparison of two of the tumor models (LNCaP and PC3 wt) in the right shoulder of
athymic nude mice, the pHe showed a trend opposite to that observed by Vavere et al.
(24). They also used LNCaP and PC3 but for tumors implanted in the flanks of
athymic nu/nu mice and for tumor volumes > 500 mm3, so the observed differences
may potentially be due to the smaller tumor size (< 400 mm3) used in our study and
the differences in tumor location (shoulder vs flank). Our goal was to use tumors with
only moderate necrosis for best comparison with tumors seen in the clinic, hence our
choice of small to medium-sized tumors. Further, we used 1H decoupled

31

P MRS,

which may influence the average chemical shift of 3-APP, since without

1

H

decoupling the signal shape and width is not only determined by T2 relaxation and the
pHe tissue distribution, but also by the multiplet structure of 3-APP (43). We did not
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find a significant relationship between tumor size and pHe for tumors < 400 mm3 (SI
Table 6), which is consistent with the data by Raghunand et al. where tumoral pH was
observed to decrease over a tumor size range of ~ 200 – 1500 mm3 (42), while not
significantly decreasing in smaller tumors (< 400 mm3). Although decreases of mean
tumor pHe and pHi with increasing tumor size have been observed in rodent tumors
when measured over a large tumor size range (40, 42), in human tumors both
decreasing pH with increasing tumor size and a lack of such a relationship have been
reported (44).
In retrospect, we find that the outcomes of measuring pH as an average do not
give a true representation of tumor acidity, as evidenced by the broad pH distributions
observed from

31

P MRS. Instead, details of pH variation within a tumor may be key,

even at the cellular level. Variations in the spatial distribution of pHe have been
reported such that gradients exist at the interface of the cellular membrane and cytosol
(45, 46), prompting us to examine the differences between cytosolic and extracellular
pH, and to derive the net proton flux (although we still needed to use average values).
We observed that the transduced PC3-CAIX and the LNCaP implants had greater
extracellular pH gradients (∆pH) than the wild type (PC3-wt) model; however, the
measured pHe values of the two models followed an opposite trend from the ∆pH
values. We rationalize that these contrasting measurements may be due to the vast
heterogeneity in tumor homeostasis and development, governed by an intricate mesh
of metabolic pathways including rate of glycolytic metabolism, expression of acid
extruding protein, and diverse buffering capacities and O2 concentrations in the blood
vessel network, to name a few (44, 47, 48). Despite these uncertainties, we observed a
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correlation of targeting with absolute pHe, where at a pHe < 6.9, higher tumor
accumulation of the radiotracer was observed, with > 3 %ID/g. However, at pHe >
6.9, measuring and imaging tumor acidity using this probe is poorly resolved. We
postulate that this may be an effect of the insertion pKa of the full construct (pKa ~
5.9).
The development and use of pHLIP variants with a higher and lower pKs of
insertion across cellular membranes, combined with favorable thermodynamics and
kinetics properties, would allow measurement of a wider dynamic range of potential
extracellular pH probed by pHLIP-technology. Also, pHLIP variants tuned over a pKa
range could expand the applicability of minimally invasive pH measurements to
applications beyond cancer. Thus, pHLIP-based acidosis imaging probes may offer a
relative read-out of distributions of pHe, which may in turn allow clinical analysis of
tumor invasiveness and regionalization. As we move forward, associating pHLIP
tumor uptake with tumor acidosis using a regional pHe map is deemed more
appropriate; these studies are currently underway.
Autoradiography and histology performed on excised tumor sections revealed a
heterogeneous distribution of

64

Cu-NOTA-Var7(D) within the tumors, again

emphasizing the need to avoid gross averaging of pH measurements to solely correlate
the target/s of our probe with markers related to acidity. We used pimonidazole (a
hypoxia tracer) and LDH-A (involved in the interconversion of pyruvate and lactate)
as markers for comparison with the pHLIP distribution, in the absence of a direct
histological marker of low pHe.

64

Cu-NOTA-Var7(D) localization appears

preferentially in perinecrotic regions (SI Fig. 5) that display high uptake of the
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hypoxia marker pimonidazole, but shows no clear relationship to the vascular
perfusion marker Hoechst 33342 (Fig. 6). The LDH-A-mediated conversion of
pyruvate to lactate is postulated to be one of the principal sources of tumor acidity (49,
50); elevated LDH-A would be expected to result in concomitant elevated pHLIP
binding.
LDH-A expression, while previously been shown to be hypoxia-regulated (via the
HIF-1 transcription factor), has not yet been individually validated as a marker of low
pHe (51). However, for these studies we took elevated expression of LDH-A as a
stable marker of regional lactic acidosis, which is not susceptible to perfusionmediated fluctuations in extracellular microenvironment (52). The predicted cellular
half-life of LDH-A is tissue-type dependent, but is generally in the order of several
days (53), which is appropriate to our experimental protocols.

The expression of CAIX, which could also be taken to indicate regions of lowered
pHe, is similarly regulated by HIF-1, and has a similar cellular half-life to LDH-A
(54). While arguably inversely related to lowered pHe, both LDH-A and CAIX
expression cannot be assumed to linearly relate to absolute pHe. Taken together with
the induced, constitutive CAIX expression in the PC3-CAIX model and the very low
observed CAIX expression in the LNCaP model, these facts render CAIX expression
an unsuitable marker for low pHe or pO2 in our study. For these reasons, we also
included pimonidazole binding in our analysis. Unlike LDH-A expression, there is no
reported protein biomarker dependence of pimonidazole uptake, and its affinity is
primarily dependent on low pO2, making pimonidazole a general marker of a hypoxic
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tumor microenvironment (55). Our data demonstrate that, in the tumor models used in
this study, LDH-A expression and pimonidazole binding have similar but discordant
spatial distributions, in good agreement with previous reports that lactic acidosis and
hypoxia are not always interdependent (10, 46, 48). It is likely that tumor regions of
poor vascularity and low pO2 will also possess excess extracellular H+ ions due to
anaerobic glucose metabolism and local lactic acidosis. While we observed a trend
towards increasing 64Cu-NOTA-Var7(D) uptake with increasing pimonidazole uptake,
the relationship appears to be non-linear (Fig. 6C-D). This may in part be due to the
effect of pHe on absolute pimonidazole uptake, although this is likely to be a minor
effect over the pHe ranges measured in this study (56).
By finding a probe that marks the acidosis inherent in tumor metabolism, we have
defined a new clinical potential for marking tumors and measuring their aggressive
characteristics. Defining a probe with usable imaging properties could allow it to be
used to follow the progression of a tumor and to monitor the effects of therapy.
Methods
Additional details of materials, methods and equipment used are found in the provided
supplemental information.
Synthesis, purification and characterization of DOTA- and NOTA-conjugates of
pHLIP. Variants of pHLIP were synthesized and purchased from C.S. Bio Co. Inc.
(Menlo Park, CA). Peptides were derivatized with either maleimido-monoamideDOTA (Macrocyclics, Inc., Dallas, TX) or p-SCN-Bn-NOTA (Macrocyclics, Inc.,
Dallas, TX).
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Radiolabeling and purification with 68GaCl3 and 64CuCl2. Radiolabeling of pHLIPDOTA or -NOTA with 68Ga or 64Cu was conducted via a microwave-assisted reaction
at 90 °C at 1 min. in 0.5 M ammonium acetate, pH ~ 5.5. Unbound radiometal was
removed via a C18 solid phase extraction cartridge (Grace, Deerfield, Il). The pure
labeled peptide was eluted with 0.5% 2 M HCl in ethanol. Radiochemical purities of >
95% were ensured before administering to animals.
Cell Culture and Growth. All tissue culture manipulations were conducted under a
laminar flow hood using aseptic technique. LNCaP prostate cancer cells were grown
as adherent monolayers in RPMI 1640 (GE Healthcare, Austria) containing 2 mM
glutamine, 10 mM HEPES, 1 mM sodium pyruvate, 4.5 g/L glucose, and 1.5 g/L
sodium bicarbonate. PC3-CAIX and PC3-wt cells were cultured in RPMI 1640
containing 2 mM L-glutamine. All media were supplemented with 10% fetal calf
serum, 100 units/mL penicillin and 100 µg/mL streptomycin. Cells were grown in a
5% CO2
and 0.53 mM EDTA in Hank’s Buffered Salt Solution (HBSS) with no calcium or
magnesium present.
In vitro cell binding. PC3-wt cells were incubated with different 68Ga-labeled pHLIPDOTA variants for 1 h at 37 °C at different pH ranging ~ 6.3 - 7.0. The cells were then
washed twice with the same media used for incubation to remove unbound activity
and the retained activity was counted using a Wizard2 2480 gamma counter (Perkin
Elmer).
pH-dependence. The pH-dependent partitioning of the peptides into lipid bilayers
using POPC liposomes was investigated by measuring the shift of the intrinsic
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fluorescence spectral maximum of the peptide as the pH is lowered from pH 8 to 2, as
previously described (25). The spectra were analyzed by decomposition algorithms
using an on-line PFAST toolkit (Protein Fluorescence and Structural Toolkit:
http://pfast.phys.uri.edu/) to obtain spectral maxima (max). Finally, the positions of
the fluorescence spectral maxima (max) of the single component solutions were
plotted versus pH and the Henderson–Hasselbalch equation was used to fit the data:
𝜆𝑚𝑎𝑥 = 𝜆2𝑚𝑎𝑥 +

(𝜆1𝑚𝑎𝑥 − 𝜆2𝑚𝑎𝑥 )
1 + 10(𝑝𝐻−𝑝𝐾𝑎)

where 1max and 2max are the beginning and end of the transition, and the pKa is the
midpoint of the transition.
Steady-state fluorescence and circular dichroism measurements. Tryptophan
fluorescence and circular dichroism (CD) measurements were carried out on a PC1
ISS spectrofluorometer (ISS, Inc.) and a MOS-450 spectrometer (Biologic, Inc.),
respectively, at 25 ºC, as previously reported (25).
Partition coefficient. The log P values (n=3) were determined for each labeled
peptide by measuring the amount of activity from equal volume of samples obtained
from the octanol and 1×PBS (pH~7) layers.
Cell transduction. Stable clones of PC3-CAIX were developed by transducing PC3wt cell with SFG-CAIX-IRES2-GFP. PC3-wt cells at ~50% confluence were
incubated with virus-containing medium for 12 hours in the presence of polybrene (8
mg/ml; Sigma, St.Louis, MO, USA) as previously described (57). Cells were sorted
several times using a fluorescence-activated cell sorter (FACS; BD Bioscience, CA,
USA) (SI Fig. 4A) with Western blot experiments confirming CAIX expression (SI
Fig. 4B).
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Animal models. All animals were treated according to the guidelines set by the
Institutional Animal Care and Use Committee. Tumors were induced in male, athymic
nu/nu mice (Taconic Farms, Inc., Hudson, NY or Harlan Laboratories, Indianapolis,
IN) on the shoulder by subcutaneous injection of 3×106 million cells of either PC3-wt,
PC3-CAIX or LNCaP cells in a 200 µL suspension of 1:1 media:Matrigel Basement
Membrane Matrix (BD Sciences, Bedford, MA). Mice were utilized once volumes
reached 150-300 mm3.
In vivo animal PET imaging and biodistribution. Imaging experiments were
accomplished with a microPET Focus 120 or R4 scanner (Concorde Microsystems).
Mice (n=3-5) were administered with 68Ga/64Cu-radiolabeled pHLIP variants (200-300
Ci, 15-25 g) in 100-200 L 0.9% saline formulations via lateral tail vein injections.
PET whole body acquisitions were recorded on mice at 1-24 h p.i., while anesthetized
with 1.5-2.0% isofluorane (Baxter Healthcare) in air. The images were analyzed using
ASIPro VMTM software (Concorde Microsystems). Regions-of-interest (ROI) were
drawn and plotted vs. time.
Biodistribution studies were performed on male athymic nu/nu mice bearing
separate subcutaneous prostate xenografts (n=3-5).
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Ga- or 64Cu-radiolabeled pHLIP

variants (20-50 Ci, 1-2 g) in 100 L 0.9 % saline were administered intravenously
on the lateral vein. At a predetermined timepoint (1-24 h), the mice were euthanized
by asphyxiation with CO2. Blood was collected immediately via cardiac puncture
while the tumor along with chosen organs was harvested. The radioactivity bound to
each organ was counted using a gamma counter. The percentage of tracer uptake
expressed as % injected dose per gram (%ID/g) was calculated as the activity bound to
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the tissue per organ weight per actual injected dose and decay-corrected to the time of
counting.
For studies demonstrating correlation of extracellular acidification and pHLIPPET, pH, PET imaging and biodistribution measurements were conducted on the same
tumors. On the same mice,

64

Cu-NOTA-Var7(D) was administered intravenously

post-MRS. PET images were acquired at 1-24 h p.i. with the mice subsequently
euthanized after the last scan for ex vivo tissue analysis. Pairing of tumors is detailed
in SI Table 6.
In Vivo pH Measurements by

1

H-decoupled

31

P Magnetic Resonance

Spectroscopy (MRS). The MR experiments were performed on a horizontal-bore 7T
MR spectrometer (Bruker, Germany) using a home-built 1H / 31P MR coil assembly.
Prior to the MR measurements, a tail vein catheter was inserted, facilitating the
administration of 3-APP via a home-built catheter line assembly during the MR
experiment. For the duration of the MR experiment, the mice were kept anesthetized
with < 2% isoflurane in 100% oxygen and the core temperature was maintained at 3437°C. A bolus of 480 mg/kg 3-APP was injected i.v. via the tail vein catheter directly
before the acquisition of a 1H-decoupled 31P MR single pulse spectrum averaged over
17 min 4 s, acquired using a 60° excitation pulse, 2 s relaxation delay, 10 kHz spectral
width, 2048 points, and 512 averages. Directly following the first acquisition, a 2nd
bolus of 480 mg/kg 3-APP was injected i.v. and a 2nd 1H-decoupled 31P MR spectrum
acquired. For each tumor, the free induction decays (FIDs) of the two 31P MR spectra
were added up, resulting in a 34 min 8 s MR spectrum, and an exponential line
broadening of 20 Hz applied. The resulting FIDs were Fourier transformed, phase
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corrected, and the α-NDP/α-NTP signal calibrated to -10.05 ppm (Fig. 4A). The MR
spectra were fitted in the time domain, using the software package XsOsNMR (kindly
provided by Dr. Dikoma Shungu and Xiaoling Mao) and the intracellular and
extracellular pH (pHi, pHe) calculated from the chemical shifts of inorganic phosphate
(Pi) and 3-aminopropylphosphonate (3-APP) respectively, described previously (43).
The inorganic phosphate signal, Pi represents primarily intracellular pH (pHi) (58, 59).
The chemical shifts δ of Pi and 3-APP relative to α-NTP at -10.05 ppm, δ(Pi) and δ(3APP) respectively, are related to pHi and pHe by their respective HendersonHasselbach equations and calculated as follows:
pHi = 6.85 + log10
pHe = 6.91 + log10

𝛿(Pi) − 0.58
3.14 − 𝛿(Pi)

𝛿(3-APP) − 21.10
24.32 − 𝛿(3-APP)

pH values were reported as the mean ± standard error of the mean (SEM).
Autoradiography and fluorescence microscopy. Animals were intravenously
administered

80

mg/kg

pimonidazole

hydrochloride

(Hypoxyprobe-1,

NPI,

Burlington, MA) in a final injection volume of 200 μL 1 h before sacrifice. Hoechst
33342 trihydrochloride (Sigma; 1mg in 100 μL of physiologic saline) was injected 5
min before euthanizing. Following sacrifice, tumors were excised and embedded in
OCT mounting medium (Optimal Cutting Temperature (OCT), Sakura Finetek, CA),
frozen on dry ice, and cut in several 10 µm sections throughout the tumor. Digital
autoradiography (DAR) was performed by placing tissue sections in a film cassette
against a phosphor imaging plate (Fujifilm BAS-MS2325) for an appropriate exposure
period at -20 ºC. Phosphor imaging plates were read at a pixel resolution of 25 μm ×
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25 μm in-plane resolution using a Typhoon FLA 7000IP (General Electric, USA)
phosphor imager.

Following autoradiographic exposure, the same or sequential

sections were then used for fluorescence and H&E staining and microscopy.
Immunofluorescence staining for pimonidazole was carried out as previously
described (54), the major difference being the use of a rabbit polyclonal antipimonidazole primary antibody (NPI). Secondary detection was carried out using goat
anti-rabbit Alexa-488 (Invitrogen, Grand Island, NY) (1:100 in blocking buffer).
Images were acquired as previously described (60). Lactate dehydrogenase A (LDHA) staining was carried out using a rabbit polyclonal anti-LDH-A antibody (Novus
Biologicals, NBP1-48336, 1:50), and secondary detection with goat anti-rabbit Alexa568 (Invitrogen). Whole tumor montage images were obtained by acquiring multiple
fields at 40× magnification, followed by alignment using MicroSuite Biological Suite
(version 2.7, Olympus USA).
Pixel re-binning and scatterplot generation
Pixel re-binning was done using an adaptation of the methods described in (61) and
(62). Briefly, registered image sets were re-sampled to 50×50×10 μm3 pixel size, each
image converted to an 8-bit grayscale image, and pixel values with their corresponding
image location recorded. The data from the DAR image was designated as
independent and the fluorescence image data as dependent. Data were then sorted in
ascending order of the independent variable while maintaining the association between
independent and dependent values. The data set was then split into deciles, each
containing the same number of data points, i.e. the 10% of the data points lowest in
terms of the independent variable, then the next lowest 10%, etc.
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Statistical Analysis
Data values were expressed as the mean ± S.D. unless otherwise stated. Statistical
analysis was performed using GraphPad Prism version 5.03 software using student’s ttest. A P value of < 0.05 is considered statistically significant.
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Tables

Table 1. Partition coefficients (mean ± S.D.) of
show different lipophilic characteristics.
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68

Ga-labeled pHLIP-DOTA variants

Table 2. Tumor-to-tissue contrast ratios obtained for the
68

Ga labeled WT and Var7 variants at 4 h p.i.

Tissue

68

Blood

0.43 ± 0.16

0.69 ± 0.18

Liver

0.40 ± 0.05

0.61 ± 0.15

Kidney

0.37 ± 0.16

0.02 ± 0.01

Muscle

2.02 ± 1.97

3.17 ± 0.91

Bone

0.25 ± 0.13

0.57 ± 0.41

Ga-DOTA-WT

68

Ga-DOTA-Var7

Table 2. Tumor-to-tissue contrast ratios (mean ± S.D., [rel. u.]) obtained for the
labeled WT and Var7 variants at 4 h p.i.
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68

Ga

Table 3. Tumor-to-tissue contrast ratios obtained for

64

Cu-

Var7 with either DOTA or NOTA as ligands.
Tissue

64

Blood

2.63 ± 0.57

0.81 ± 0.22

Liver

0.28 ± 0.08

1.56 ± 0.40

Kidney

0.08 ± 0.01

0.39 ± 0.17

Muscle

7.81 ± 1.78

7.81 ± 0.88

Bone

1.94 ± 0.41

6.04 ± 2.34

Cu-DOTA-Var7

64

Cu-NOTA-Var7(D)

Table 3. Tumor-to-tissue contrast ratios (mean ± S.D. [rel. u.]) obtained for 64Cu-Var7
with either DOTA or NOTA as ligands at 24 h p.i.
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Figures

Figure 1.

68

Ga-DOTA-labeled pHLIP variants. In vitro binding studies (n=3)

display higher binding of

68

Ga-DOTA-WT and

68

Ga-DOTA-Var7 variants as the pH

of the incubation medium is decreased. Note that the opposite was observed with the
control peptide, K-WT.
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Figure 2. In vivo pharmacokinetic optimization studies in prostate tumor
xenografts. Tissue distribution analysis of

68

Ga-DOTA-labeled WT and Var7

demonstrate superiority of the latter in terms of tumor uptake at 4 h p.i. in PC3-wt
tumor implants (A); in the same tumor model, the distribution of 64Cu-NOTA-Var7(D)
displays faster clearance and less non-specific binding of the NOTA scaffold,
particularly in hepatobiliary (L=liver), intestinal (I=intestines) and renal (K=kidneys)
tissues, in contrast to

64

Cu-DOTA-Var7. However, tumor uptake of both probes was

comparable at 24 h p.i. (B); acquired PET images (C, D) from 1-24 h were consistent
with the biodistribution data (A, B) for both LNCaP and PC3-wt xenografts. The PET
images clearly demonstrate the advantages of 64Cu-NOTA-Var7(D) compared to 64CuDOTA-Var7, due to more rapid clearance from hepatobiliary and intestinal tissues.
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Figure 3. pH-dependent interaction of Cu-NOTA-Var7(D) with the lipid
membrane bilayer. Cold Cu-NOTA-Var7(D) was studied for the presence of the
three basic states of pHLIP; state I is the peptide in solution at pH 8; state II is the
peptide in the presence of POPC liposomes at pH 8; state III is the folding and
insertion of the peptide with POPC liposomes from pH 8 to 3.6. The states were
monitored by changes of the steady-state circular dichroism (the spectra D-version of
the peptide were multiplied by -1) (A) and tryptophan fluorescence spectroscopy at λex
= 295 nm (B). Changes in the intrinsic fluorescence of the construct were monitored
as a function of pH as a result of the peptide’s insertion wherein a pKa ~ 5.9 was
obtained (C). The values obtained from the results of analyzed spectral data are given
in SI Table 5.
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Figure 4. In vivo pHe measurements. Representative 1H-decoupled 31P MR spectrum
of a PC3-CAIX tumor after 3-APP injection. Signal assignments are: 3aminopropylphosphonate (3-APP), phosphoethanolamine (PE), phosphocholine (PC),
inorganic phosphate (Pi), phosphocreatine (PCr), nucleoside di- and triphosphates
(NDP/NTPs) (A); pHe measurements among three prostate tumor models show PC3wt as the most acidic (6.93 ± 0.03, P = 0.035) compared to the PC3-CAIX (7.07 ±
0.06) and LNCaP (7.07 ± 0.04) xenografts (B); The intracellular acidity of PC3-wt
(6.94 ± 0.07, P = 0.012) is higher than the other prostate implants (C); positive proton
fluxes, corresponding to a respective extracellular to intracellular pH gradient, are
observed for PC3-CAIX (0.33 ± 0.13, n=5, P = 0.018) and LNCaP (0.27 ± 0.10, n=5,
P = 0.020) tumors, but not for PC3-wt tumors (-0.010 ± 0.055, n=5) (D).
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Figure 5. Tumor uptake of pHLIP-PET shows a direct association with
extracellular acidity. An increasing trend of

64

Cu-NOTA-Var7(D) uptake was

displayed as the pHe of the PC3-wt tumor model decreases (A); A plot of the pHe
against tumor uptake (%ID/g, 24 h p.i.) of the radiotracer for data pooled from all
three tumor models demonstrate a notable threshold where higher probe accretion
(>3%ID/g) correlates to a very acidic extracellular space with pHe < 6.9 (B).
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Figure 6. Histology and autoradiography.

64

Cu-NOTA-Var7(D) autoradiography

(24 h p.i.) and correlative histology from 10 μm adjacent sections obtained from
representative PC3-CAIX (A), LNCaP (B), and PC3-WT (C) tumors. The
distributions of 64Cu-NOTA-Var7(D) (white), pimonidazole (hypoxia, green) Hoechst
33342 (perfusion, blue), and expression of LDH-A (red) are shown (Bar = 2 mm).
White arrows indicate examples of discordance between pimonidazole uptake and
LDH-A expression. Red arrows indicate accumulation of 64Cu-NOTA-Var7(D) on the
skin. Re-binned pixel-by-pixel scatterplots, derived from the PC3-CAIX, LNCaP and
PC3-wt sections shown in A-C respectively, show the relationship between
autoradiographic counts and the staining intensity of the markers pimonidazole, LDHA and Hoechst 33342 (D-F).
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Supplementary Information

Materials and Methods
All chemicals were obtained from Sigma Aldrich (St. Louis, MO), unless stated
otherwise. Removal of trace metals from ultrapure water (>18.2 MΩ·cm at 25 ºC,
Milli-Q, Millipore, Billerica, MA) was performed by soaking overnight in Chelex 100
resin (Bio-Rad Laboratories, Hercules, CA) at a ratio of 5 g per 100 ml. Radioactivity
doses were measured with a Capintec CRC-55tR Dose Calibrator (Capintec, Ramsey,
NJ). Samples with radioactivity were scanned on a calibrated Perkin Elmer (Waltham,
MA) Automatic Wizard2 gamma counter which was set to decay correct at the start of
the assay.

68

Ga/64Cu-radiolabeling reactions were monitored by using silica-gel

impregnated glass-fiber instant thin-layer chromatography (ITLC-SG) paper (Pall
Corp., East Hills, NY) and analyzed on a radio-ITLC plate reader (Bioscan System
200 Imaging Scanner) coupled to a Bioscan Autochanger 1000 (Bioscan Inc.,
Washington, DC), using Win-Scan Radio-TLC software v3.0.
Liposome preparation. Large unilamellar vesicles (LUVs) were prepared by
extrusion: 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC, Avanti Polar
Lipids, Inc.) dissolved in chloroform was de-solvated on a rotary evaporator and dried
under vacuum for several hours. The phospholipid film was then rehydrated in 10 mM
phosphate buffer pH 8.0, vortexed until the lipid layer was completely dissolved in
buffer, and repeatedly extruded through membranes with 50 nm pore sizes to obtain
LUVs.
Analytical

ultra-centrifugation

measurements.

Sedimentation

velocity

measurements were carried out on a Beckman XL-I ultra-centrifuge with a Beckman
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XL-A absorbance meter under temperature control. The states of Cu-NOTA-pHLIP
constructs at 8 µM in 10 mM phosphate buffer (pH 8) were investigated. Loaded
sample cells were placed inside the centrifuge for at least 3 hours before starting the
experiment to allow the temperature to be equilibrated to 20 oC and the vacuum to
reach 50 μm Hg. Measurements were made at 42K RPM following the peptide by
absorbance at 280 nm for each cell every minute for approximately 20 hours. This
resulted in acquiring at least 200 data points for each set of sample. The resulting data
were then analyzed using SEDFIT software (NIH, Bethesda, MD). The buffer
viscosity and density values were calculated with SEDNTERP (Biomolecular
Interaction Technologies Center at the University of New Hampshire), and were set as
0.01005 and 0.99967 respectively. Values for the partial specific volume and F-ratio
were 0.73 and 0.95, respectively. The distribution of sedimentation coefficients
obtained for each construct was analyzed using Gaussian fitting functions.
Generation of SFG-CAIX-IRES2-GFP vector. All DNA manipulations were
performed using restriction enzymes, T4 DNA ligase, and buffers according to
standard procedures and manufacturer's instructions (New England BioLabs, CA,
USA). The retroviral vector SFG-FLuc-IRES2-GFP (1) was used to generate a new
retroviral vector SFG-CAIX-IRES2-GFP. To construct the SFG-CAIX-IRES2-GFP
vector, the gene of full length CAIX cDNA was amplified from pCMV6-ENTRY
plasmid with human CAIX (carbonic anhydrase IX) cDNA (NM_001216) linked with
two tags Myc-DKK (# RC204839, OriGene Tech, MD, USA). Amplification of the
CAIX gene was performed by PCR using one primer for the 5’ end of cDNA that
incorporated the SgfI restriction site 5’- GCGATCGCCATGGCTCCCCTGTGCC-3’
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and a 2nd primer 5’-GGAAGATCTTTAAACCTTATCGT-3’, bearing the BglII
restriction site. The resulting PCR product was used for SgfI/BglI ligation into the
SFG-FLuc-IRES2-GFP backbone to obtain the final plasmid SFG-CAIX-IRES2-GFP
where the CAIX gene was separated from the GFP by an IRES element. SFG-CAIXIRES2-GFP retroviral plasmid was transfected into a GPG293 producer cell line using
LipofectAMINE 2000 (Invitrogen, CA), as described previously (2). The retroviruscontaining medium was collected over four consecutive days and stored at -80°C.
Western blotting. Cell preparations were extracted using Mammalian Protein
Extraction Reagent (Pierce, Rockford, IL, USA). Protein concentrations were
determined by Bio-Rad protein assay (Bio-Rad, Hercules, CA, USA). The proteins in
equivalent amounts (10-40 µg/well) were separated by electrophoresis in a NuPAGE
gradient 4-12% bis-Tris Gel (Invitrogen, Carlsbad, CA, USA) and were immunoblotted with anti-CAIX antibody (Epitomics Inc., CA, USA) at a 1:1000 dilution,
anti-DKK and anti-Myc antibodies (OriGene Tech, MD, USA) at 1:1000 dilution, and
anti-ß-actin antibodies (Abcam Inc., Cambridge, MA, USA) at a 1:5000 dilution.
Immune complexes were detected by horseradish-peroxidase labeled antibodies and
enhanced chemiluminescence reagent (Amersham, Buckinghamshire, UK).
MRS
The MR experiments were performed on mice using a horizontal-bore 7T MR
spectrometer (Bruker, Germany), employing a home-built 1H / 31P MR coil assembly.
Prior to the MR measurements, a tail vein catheter was inserted, facilitating the
administration of 3-APP via a home-built catheter line assembly during the MR
experiment. For the duration of the MR experiment, the mice were kept anesthetized
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with < 2% isoflurane in 100% oxygen and the core temperature was maintained at 3437°C. The breathing rate, monitored using a pressure sensor, was kept at 50-80
breath/min by adjusting the isoflurane level. The rodent core temperature was
maintained at 34-37°C using an MR-compatible, small rodent Heater System. After
tuning and matching of the 1H and 31P MR coils, the water line width across the tumor
was optimized to 35-80 Hz full-width-half-maximum using field map-based
shimming. Two baseline 1H-decoupled 31P MR single pulse spectra, averaged over 17
min 4 s, each were acquired using a 60° excitation pulse, 2 s relaxation delay, 10 kHz
spectral width, 2048 points, and 512 averages. Following these, a bolus of 480 mg/kg
3-APP was injected i.v. via the tail vein catheter directly before the acquisition of
another 1H-decoupled

31

P MR spectrum; directly following the first post-APP

acquisition, a 2nd bolus of 480 mg/kg 3-APP was injected i.v. and a 2nd 1H-decoupled
31

P MR spectrum acquired. For each tumor, the free induction decays (FIDs) of the

two

31

P MR spectra, before and after 3-APP injection respectively, were added up,

resulting in a 34 min 8 s MR spectrum for each, and an exponential line broadening of
20 Hz applied. The resulting FIDs were Fourier transformed, phase corrected, and the
α-NDP/α-NTP signal calibrated to -10.05 ppm (Fig. 4A). The MR spectra were fitted
in the time domain, using the software package XsOsNMR (kindly provided by Dr.
Dikoma Shungu and Xiaoling Mao) and the intracellular and extracellular pH (pHi,
pHe) calculated from the chemical shifts of inorganic phosphate (Pi) and 3aminopropylphosphonate (3-APP) respectively, as described in detail previously (3).
As the inorganic phosphate signal in tumors is predominantly comprised of
intracellular Pi, due to the densely-packed cells, the pH calculated from its chemical
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shift represents primarily intracellular pH (pHi) (4, 5). The chemical shifts δ of Pi and
3-APP relative to α-NTP at -10.05 ppm, δ(Pi) and δ(3-APP) respectively, are related to
pHi and pHe by their respective Henderson-Hasselbalch equations and calculated as
follows:
pHi = 6.85 + log10
pHe = 6.91 + log10

𝛿(Pi) − 0.58
3.14 − 𝛿(Pi)

𝛿(3-APP) − 21.10
24.32 − 𝛿(3-APP)

pH values were reported as the mean ± standard error of the mean (SEM).
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Supplementary Tables
SI Table 1. Tissue uptake (mean %ID/g ± S.D.) of 68Ga-DOTA-WT administered via
lateral tail vein in male, athymic nu/nu mice bearing PC3-wt prostate cancer
xenografts.
1h
2h
4h
Tissue
n=4
n=4
n=4
Blood
13.78 ± 2.56
10.55 ± 2.07
6.94 ± 1.51
PC3 tumor
1.87 ± 0.45
2.36 ± 0.40
2.86 ± 0.75
Heart
3.99 ± 1.28
3.26 ± 0.73
2.63 ± 0.62
Lungs
6.67 ± 1.60
4.83 ± 0.26
3.17 ± 1.16
Liver
7.21 ± 2.43
5.22 ± 0.68
5.79 ± 1.91
Spleen
2.87 ± 0.53
2.28 ± 1.26
4.36 ± 1.78
Stomach
0.60 ± 0.20
0.66 ± 0.24
0.80 ± 0.31
Small
1.29 ± 0.55
1.36 ± 0.13
1.50 ± 0.46
intestines
Large
0.37 ± 0.09
0.29 ± 0.08
0.66 ± 0.31
intestines
Kidney
6.38 ± 2.39
7.60 ± 2.00
8.15 ± 1.98
Muscle
0.76 ± 0.33
0.67 ± 0.29
1.67 ± 1.55
Bone
2.09 ± 0.97
4.67 ± 3.37
5.31 ± 4.49
Brain
0.34 ± 0.17
0.30 ± 0.12
0.55 ± 0.11

Tumor/Blood
Tumor/Liver
Tumor/Kidney
Tumor/Muscle
Tumor/Bone

Contrast calculated as Tumor to Organ Ratio [rel. u.]
0.12 ± 0.02
0.23 ± 0.02
0.43
0.27 ± 0.02
0.45 ± 0.03
0.40
0.30 ± 0.05
0.32 ± 0.05
0.37
2.14 ± 0.40
3.92 ± 1.26
2.02
1.09 ± 0.67
0.80 ± 0.63
0.25
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±
±
±
±
±

0.16
0.05
0.16
1.97
0.13

SI Table 2. Tissue uptake (mean %ID/g ± S.D.) of 68Ga-DOTA-Var7
administered via lateral tail vein in male, athymic nu/nu mice bearing PC3-wt
prostate cancer xenografts.
1h
2h
4h
Tissue
n=4
n=5
n=4
Blood
4.54 ± 0.69
6.49 ± 1.62
7.46 ± 2.80
PC3 tumor
2.47 ± 0.19
4.37 ± 1.46
5.60 ± 0.30
Heart
2.15 ± 0.38
3.13 ± 0.36
2.89 ± 1.10
Lungs
4.18 ± 0.67
5.07 ± 0.86
5.26 ± 0.52
Liver
4.01 ± 0.37
4.39 ± 0.53
8.30 ± 2.14
Spleen
4.12 ± 0.68
5.29 ± 0.30
9.26 ± 1.52
Stomach
1.46 ± 0.33
2.35 ± 0.57
3.05 ± 0.94
Small
2.53 ± 0.29
2.86 ± 0.17
5.38 ± 2.02
intestines
Large
1.21 ± 0.17
1.56 ± 0.45
7.73 ± 1.06
intestines
Kidney
103.54 ± 13.23
134.40 ± 32.79
332.24 ± 118.92
Muscle
1.00 ± 0.16
2.03 ± 0.46
5.16 ± 7.34
Bone
6.62 ± 1.87
14.39 ± 1.95
13.33 ± 9.87
Brain
0.52 ± 0.11
0.79 ± 0.16
0.55 ± 0.32
Contrast calculated as Tumor to Organ Ratio [rel. u.]
Tumor/Blood
0.55 ± 0.05
0.72 ± 0.30
0.69
Tumor/Liver
0.62 ± 0.04
0.87 ± 0.47
0.61
Tumor/Kidney 0.020 ± 0.002
0.03 ± 0.01
0.020
Tumor/Muscle 2.51 ± 0.25
2.28 ± 0.75
3.17
Tumor/Bone
0.39 ± 0.09
0.39 ± 0.14
0.57
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±
±
±
±
±

0.18
0.15
0.006
0.91
0.41

SI Table 3. Tissue uptake (mean %ID/g ± S.D.) of 64Cu-DOTA-Var7
administered via lateral tail vein in male, athymic nu/nu mice bearing PC3-wt
prostate cancer xenografts.
1h
4h
24 h
Tissue
n=5
n=5
n=5
Blood
1.89 ± 0.70
0.68 ± 0.05
0.63 ± 0.13
PC3 tumor
1.19 ± 0.55
1.45 ± 0.19
1.64 ± 0.38
Heart
0.95 ± 0.28
0.71 ± 0.08
0.86 ± 0.17
Lungs
1.33 ± 0.35
1.16 ± 0.34
1.61 ± 0.28
Liver
5.03 ± 1.33
4.83 ± 0.90
6.05 ± 1.36
Spleen
1.08 ± 0.59
1.05 ± 0.36
1.95 ± 0.27
Stomach
0.67 ± 0.34
0.95 ± 0.45
0.72 ± 0.26
Small
1.72 ± 0.82
1.46 ± 0.14
1.29 ± 0.20
intestines
Large
0.56 ± 0.21
2.17 ± 0.70
2.38 ± 0.69
intestines
Kidney
27.98 ± 8.62
32.24 ± 7.90
19.59 ± 3.99
Muscle
0.26 ± 0.05
0.15 ± 0.02
0.21 ± 0.02
Bone
0.88 ± 0.38
1.02 ± 0.50
0.87 ± 0.23
Brain
0.07 ± 0.03
0.11 ± 0.04
0.10 ± 0.05
Contrast calculated as Tumor to Organ Ratio [rel. u.]
Tumor/Blood
0.63 ± 0.16
2.15 ± 0.27
2.63
Tumor/Liver
0.24 ± 0.08
0.31 ± 0.04
0.28
Tumor/Kidney 0.05 ± 0.02
0.05 ± 0.01
0.08
Tumor/Muscle 4.59 ± 1.58
10.24 ± 2.46
7.81
Tumor/Bone
1.44 ± 0.59
1.18 ± 0.19
1.94
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±
±
±
±
±

0.57
0.08
0.01
1.78
0.41

SI Table 4. Tissue uptake (mean %ID/g ± S.D.) of 64Cu-NOTA-Var7(D)
administered via lateral tail vein in male, athymic nu/nu mice bearing PC3-wt
prostate cancer xenografts.
1h
4h
24 h
Tissue
n=5
n=5
n=5
Blood
2.81 ±
0.76
2.14 ± 0.76
1.67 ± 0.21
PC3 tumor
1.62 ±
0.24
1.07 ± 0.33
1.36 ± 0.43
Heart
0.95 ±
0.13
0.84 ± 0.31
0.79 ± 0.10
Lungs
2.55 ±
0.51
1.33 ± 0.75
1.02 ± 0.25
Liver
2.25 ±
0.67
2.07 ± 0.89
0.88 ± 0.26
Spleen
0.75 ±
0.11
0.41 ± 0.14
0.38 ± 0.23
Stomach
0.52 ±
0.27
0.69 ± 0.44
0.28 ± 0.09
Small
22.78 ±
16.42
1.16 ± 0.30
0.37 ± 0.06
intestines
Large
15.37 ±
5.76
27.64 ± 3.50
0.53 ± 0.11
intestines
Kidney
13.27 ±
0.65
5.84 ± 0.89
3.86 ± 1.14
Bone
0.55 ±
0.18
0.20 ± 0.09
0.20 ± 0.04
Muscle
0.72 ±
0.55
0.34 ± 0.27
0.27 ± 0.17

Tumor/Blood
Tumor/Liver
Tumor/Kidney
Tumor/Muscle
Tumor/Bone
Tumor/Sm.
Intestines

Contrast calculated as Tumor to Organ Ratio [rel. u.]
0.60 ±
0.09
0.43 ± 0.17
0.81
0.75 ±
0.15
0.46 ± 0.20
1.56
0.11 ±
0.01
0.13 ± 0.04
0.39
3.13 ±
0.79
4.25 ± 0.64
7.81
3.05 ±
1.41
0.36 ± 2.99
6.04
0.14

±

0.15
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±

0.69

3.71

±
±
±
±
±

0.22
0.40
0.17
0.88
2.34

±

1.04

SI Table 5. The apparent pK (pKa) of pHLIP peptide insertion into membrane, the
sedimentation coefficients (Sed. Coeff.) and calculated molecular masses of the
peptides in solution at pH 8.0, and the spectral parameters of peptides in the states
I, II and III are presented. The spectral parameters were obtained from the analysis
of the fluorescence and CD spectra: the maximum position of the fluorescence
spectrum m, S – the normalized area under the spectra (normalized with respect to
the area under the spectrum of pHLIP in state I); 225 x 103, deg cm2 dmol-1 – the
molar ellipticity at 225 nm.
pK
a

Sed. Coef. / Mass /
Mol. weight (kDa)

State I

State II

State III

Var7

5.9

1.04/7.03/3.58

348 /1.0/3.18

345/1.39/3.05

337/2.62/5.03

Var5

5.5

1.16/7.31/3.73

352/1.0/2.44

347/1.64/2.88

339/1.79/7.16

m / S / 225 x103

340/1.0/340/1.21/340/3.38/6.80
6.19
7.23
* The pKa was not calculated for WT, since there is no shift of the position of
maximum of fluorescence spectra between states I, II and III.
WT

--*

1.52/14.30/4.68
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SI Table 6. Table detailing the values obtained from the independent in vivo MR,
in vivo PET, and ex vivo experiments performed and the corresponding pairing as
used in the figures. Tumors used for autoradiography and immunohistochemistry
(green highlight) were not used for biodistribution studies. Abbreviations: BL pHi –
intracellular pH before 3-APP injection, pHi – intracellular pH after 3-APP
injection, pHe – extracellular pH determined from 3-APP signal, ΔpHi = BL pHipHi, ΔpH = pHi-pHe, T – tumor, T/M – tumor to muscle ratio. Data in red depict
experiments with missing values, and were not included in the analyses.
Tumor
Type
PC-3
wt - RS

PC-3CA-IX
- RS

LNCaP
- RS

In Vivo MRS

Ex Vivo
Biodistribution

In Vivo PET

Size

BL pHi

pHi

pHe

ΔpHi

ΔpH

1h

4h

24 h

248
185
104
254
95

7.12

7.11

6.99

0.00

0.12

7.02
6.78
7.299

6.92
6.85

6.94
6.83

0.09
-0.07

-0.02
0.02

2.12
1.26
1.82
0.86

1.99
1.54
1.67
0.85

1.61
1.58
1.39
0.79

1.20
1.25
2.14
0.84

5.29
2.49
7.90
7.02

189
209
151
169
168
156
271
161
157
160

7.25
7.47
7.29
7.35
7.12
7.02
7.03
6.96
6.72
6.89

7.12
7.35
7.78
7.44
7.12
7.23
6.95
7.07
6.72
6.85

7.01
7.00
6.95

0.13
0.12
-0.49
-0.08
0.00
-0.21
0.08
-0.10
0.00
0.04

0.11
0.35
0.83
0.08
0.16
-0.36
0.22
0.00
-0.02

3.26
2.77
0.80
2.19
1.75
1.73
0.72
2.64
4.36

2.02
2.09
0.89
2.27
1.78
1.65
0.80
2.40
2.13

1.56
1.72
0.80
2.09
1.30
1.30
0.85
1.27
5.06

1.37
1.62
0.90
IHC
1.10
0.97
0.89
3.08
6.66

5.64
8.22
3.71
IHC
6.90
6.01
5.41
12.52
12.73

287
344
314
338
128
113
167

7.15
7.32
7.43
7.08
7.30
7.34
7.24

7.23
7.40
7.26
7.05
7.60
7.27
7.17

7.18
7.12

0.05
0.28

4.43
2.27

6.19
2.40

5.14
2.42

1.79
1.41

2.70
9.74

0.65
0.23
0.12

1.94
3.10
1.84
1.63

2.40
3.72
0.66
1.06

2.27
2.74
0.45
0.81

1.92
IHC
0.29
0.23

16.24
IHC
0.10
0.03

7.04
7.07
7.31
6.84
6.86
6.87

6.95
7.04
7.05

-0.08
-0.09
0.18
0.03
-0.30
0.07
0.07
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Supplementary Figures

SI Fig. 1 Serial PET images of a representative PC3-wt prostate tumor obtained after 1
h, 2 h and 4 h post injection of 68Ga-DOTA-WT, demonstrating non-specific binding
of the pHLIP variant to healthy tissue (e.g. liver, kidney). The white circle delineates
the subcutaneous shoulder tumor.
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SI Fig. 2 Serial PET images with 68Ga-DOTA-Var7 in PC3-wt prostate models
acquired after 1-4 h p.i., demonstrating poor tumor-to-background contrast. The white
circle delineates the subcutaneous shoulder tumor.
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SI Fig. 3 pH-dependent interactions of Cu-NOTA-Var5 and Cu-NOTA-WT with a
lipid membrane bilayer. The constructs were studied for the presence of the three basic
states of pHLIP; state I is the peptide in solution at pH 8; state II is the peptide in the
presence of POPC liposomes at pH 8; state III is the folding and insertion of the
peptide with POPC liposomes from pH 8 to 3.6. The states were monitored by changes
of the steady-state circular dichroism (A, D) and tryptophan fluorescence at λex = 295
nm (B, E) spectroscopy for Cu-NOTA-Var5 (A, B) and Cu-NOTA-WT (D, E),
respectively. Changes in the intrinsic fluorescence of the Cu-NOTA-Var5 were
monitored as a function of pH as a result of the peptide’s insertion wherein a pKa ~
5.5 was obtained (C). The oligomeric states of Cu-NOTA-Var5 (Var5), Cu-NOTAVar7(D) (Var7) and Cu-NOTA-WT (WT) were investigated by analytical
ultracentrifugation, the obtained sedimentation coefficients for all constructs in buffer
at pH 8 are shown in F. The spectral data were analyzed and resulting values are given
in SI Table 5.
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SI Fig. 4 CAIX transduction in PC3-wt cells. PC3-wt cells were transduced with the
SFG-CAIX-IRES-GFP vector and sorted several times to select the populations of
GFP-expressing cells (A). Higher levels of CAIX expression in sorted cells (PC3CAIX) than in PC3-wt cells was confirmed by Western blotting of PC3-wt and CAIXtransduced PC3 cells (B).
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SI Fig. 5 64Cu-NOTA-Var7(D) autoradiography (24 h p.i.) and correlative histology
from 10 μm adjacent sections obtained from representative PC3-CAIX (A), LNCaP
(B), and PC3-WT (C) tumors. Comparison of 64Cu-NOTA-Var7(D) distribution
versus H&E staining of a sequential 10 µm section adjacent to the one used for
autoradiographic evaluation. Areas containing skin and regions of tumor necrosis are
clearly visible. Bar = 2 mm.
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Abstract
Small angle x-ray scattering studies showed membrane thinning by 18% induced by
insertion of short-pHLIP (truncated version of pH Low Insertion Peptide) into bilayer.
Thinning allows to reduce stress on membrane associated with negative hydrophobic
mismatch. Also we observed 12% of membrane thinning when long-pHLIP partitions
into outer leaflet of bilayer at high pH adopting coil conformations. The long-pHLIP
at high pH creates an asymmetric inclusion in the bilayer, which results in increase of
tension leading to the bilayer thinning. The tension and thinning is released when
long-pHLIP inserts into bilayer as a transmembrane helix at low pH.
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Introduction
Membrane-associated folding is accompanied by the insertion of a polypeptide into
the heterogeneous environment of a lipid bilayer of membrane. The stability of folded
structures in a membrane is determined by the match between the thickness of the
bilayer and the hydrophobic length of the transmembrane (TM) segments (1-4).
Hydrophobic mismatch results in significant energetic penalties, which can lead to
structural perturbations in a polypeptide, alteration in a polypeptide’s mobility and/or
membrane thickness changes (5-7).

Here we have performed a comparative investigation of long and short pHLIPs (pH
Low Insertion Peptides) interactions with the lipid bilayer of a membrane. LongpHLIPs are well investigated water-soluble membrane polypeptides, which insert into
a lipid bilayer and form a stable TM alpha-helix as a result of a drop in pH (8-11). The
insertion of the peptides of pHLIP family is employed for the targeting of acidic
diseased tissue including tumors and intracellular delivery of polar cell-impermeable
cargo molecules across membrane (8, 12-15).

Truncated versions of pHLIPs (short-pHLIP), if inserted into membrane, should create
negative hydrophobic mismatch. We used several spectroscopic assays to prove that
short-pHLIP’s interaction with a lipid bilayer at low pH leads to the membrane
inserted state of the peptide. Small angle x-ray scattering (SAXS) experiments
performed on long and short peptides allowed us to demonstrate the thinning of a lipid
bilayer of membrane as a result of short-pHLIP’s insertion into the bilayer. The
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experimental design was based on the comparison between interactions with
membranes of well-characterized long-pHLIPs and truncated short-pHLIP.

Methods and Materials
The detailed information about all methods could be found in Supporting Information.
All peptides were synthesized and purified at W.M. KECK Biotechnology center at
Yale. The peptides were dissolved either directly in buffer or 3 M urea and then
centrifuge to remove large aggregates or passed through G-10 column to remove urea,
respectively. Concentrations of the peptides were calculated spectrophotometrically by
measuring absorbance at 280 nm. Large unilamellar and multilamellar vesicles were
prepared by extrusion. Lipids were dissolved in chloroform, desolvated in a rotary
evaporator and dried under high vacuum followed by rehydration and extrusion.

Steady-state fluorescence and circular dichroism (CD) signals were measured for the
peptides in absence and presence of POPC liposomes at pH 8.0 and 4.0. The
quenching of tryptophan fluorescence of the peptides by acrylamide or 10doxylnonadecane (10DN) was performed in the presence of POPC liposomes without
and with 10% of the lipids replaced by 10DN at pH 8.0 and pH 4.0. Acrylamide was
added to the samples containing POPC liposomes without 10DN. The peptide
concentration in all samples was kept constant. Asymmetrically NBD-labeled POPC
liposomes (labeled at inner leaflet) were incubated with the peptides and FRET from
tryptophan residues to NBD at inner leaflet of the bilayer was monitored.
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Synchrotron SAXS measurements were carried out at beamline ID02 of the ESRF in
Grenoble, France (16). The measured two dimensional SAXS patterns were
normalized to an absolute intensity scale using the standard procedure and azimuthally
averaged to obtain the intensity profile as a function of q. The background buffer was
also measured and subtracted from each averaged sample intensity profile before
fitting the data.

Results
The main focus of our research is an investigation of interactions with lipid bilayer of
membrane of short-pHLIP peptide, which is a truncated version of full-length pHLIPs
(long-pHLIPs). Our experimental strategy is a comparison between membrane
interactions of short-pHLIP and well-characterized long-pHLIPs.
Short-pHLIP:

AEQNPIYWARYADLLFPTTLAW

Long-pHLIP:

AEQNPIYWARYADWLFTTPLLLLDLALLVDADET

Long-pHLIP*:

AEDQNPYWRAYADLFTPLTLLDLLALWDG

In the dual quenching and FRET spectroscopic assays we used long-pHLIP* peptide
(with truncated flanking sequence), which has Trp residues located at the beginning
and end of TM part, as in a short-pHLIP. We demonstrated previously truncated long
pHLIP adopts TM helical orientation in membrane at low pH similar to a full-length
long-pHLIP (11). We also attempted to investigate single-Trp mutants of short and
long pHLIPs with the goal of simplifying the interpretation of spectroscopic data.
However we found that some single-Trp mutants of short peptide did not exhibit pHdependent properties and most probably do not insert into membrane (further
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investigation is needed). Therefore, here we present results obtained with long and
short pHLIPs containing both tryptophan residues.

Previously we demonstrated that long-pHLIPs insert into the lipid bilayer of
membranes and form TM helices in a result of a drop in pH, and we used fluorescence
and circular dichroism (CD) spectroscopic methods to monitor transitions (8-11). Here
we show that short-pHLIP also exhibits very similar pH-dependent changes of CD
signal, increase of tryptophan fluorescence and short wavelengths shift of the
spectrum (Figure 1). Two negative peaks around 208-210 and 222-225 nm observed
on CD spectra at low pH (Figure 1b, red line) are indicative of helical structure
appearance. However, the overall strength of the CD signal was less than half
compared to the signal of long pHLIPs (8), and the first minimum (at 208-210 nm) has
higher amplitude compared to the second one at 222-225 nm. The CD signal could be
attributed to the presence of a mixture of -helical structures and random coil
conformations or formation of a 310 helix. Usually, the overall strength of the CD
signal for 310 helix is lower than for -helix. Additionally its ratio of 222/208 nm < 1
(it is in the range of 0.3-0.4) compared to the same ratio for an -helix (17).

To establish location of tryptophan residues (thus pHLIPs) within a lipid bilayer of
membrane a dual quenching assay was employed (18). Effective quenching of Trp
fluorescence by acrylamide occurs when tryptophan residues are exposed to polar
parts of the outer or inner leaflets of a bilayer. At the same time tryptophan residues
located in the middle of a membrane could be effectively quenched by another
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quencher of tryptophan fluorescence, 10DN. We performed dual-quenching assay at
pH 8.0 and pH 4.0 for short and long pHLIPs both containing Trp residues at the
beginning and end of the expected TM region of the peptides (Figure 2). At pH 8.0
short-pHLIP just barely partitions into the bilayer and therefore tryptophan
fluorescence is quenched by acrylamide very well (Figure 2a and Table 1). LongpHLIP* being more hydrophobic, is located much deeper into the bilayer, which
correlates well with our previous data (11, 19). Lowering the pH reduces quenching of
Trp fluorescence by acrylamide (from 79.1 to 48.1% for short-pHLIP and from 44.1 to
31.1% for long-pHLIP) and increases quenching by 10DN (from 12.3 to 34.7% for
short-pHLIP and from 32.7 to 44.6% for long-pHLIP) (see Figure 2 and Table 1). The
overall trend of short-pHLIP’s partition into bilayer at low pH is similar to longpHLIP’s. However, Trp residues in short-pHLIP are more exposed to acrylamide
compared to Trp residues of long-pHLIP. According to our published data the
truncated peptides have a lower affinity to the bilayer compared to long pHLIPs (8),
thus higher amount of short-peptides could be found in solution, which will lead to the
enhanced quenching by acrylamide.

The dual-quenching assay provides information about degree of partitioning of Trp
residues into bilayer. However it does not allow distinguishing between the inner or
outer leaflets location of acrylamide-accessible Trp residues. To further investigate
location of tryptophan residues in membrane we also performed NBD-FRET assay
(20, 21). First, symmetrically-labeled (with NBD dye) POPC liposomes were
prepared. Then, membrane-impermeable dithionite was used to chemically modify and

108

quench the fluorescence of NBD in outer leaflet of the bilayer, followed by the
removal of dithionite by gel filtration. As a result, asymmetrically-labeled liposomes
with NBD at the inner leaflet were obtained. The absence of potential flip-flopping of
lipids was accessed by absence of quenching of NBD fluorescence by addition of
dithionite. FRET was monitored from the tryptophan residues of peptides to NBD.
Energy transfer occurs when both fluorophores (Trp and NBD) are in a close
proximity to each other (the Förster distance for Trp-NBD donor-acceptor pair is
about 10 Å (22)). Thus, when tryptophan residues are located in the outer leaflet of the
bilayer, there is no any significant energy transfer to NBD at the inner leaflet. This is
the situation that was observed at pH 8.0 for both peptides, but was less pronounced
for long-pHLIP, which partitions deeper into the membrane. At the same time, at low
pH the FRET signal was comparable for both peptides (Figure 3b, d, red lines). We
observed that the NBD fluorescence signal increased by 11.7 and 12.9 times for shortpHLIP and long-pHLIP, respectively, in the presence of POPC at low pH compared to
the baseline. It indicates that Trp residues (located at the C-terminus) in long and short
pHLIPs both are in close proximity to the headgroups of inner leaflet of bilayer. Thus,
we can conclude that short-pHLIP inserts into lipid bilayer of membrane and spans
bilayer similar to long-pHLIP.

When a short peptide is inserted into a membrane, as it is well known, a hydrophobic
mismatch is created. We already mentioned about the possibility of presence of some
elements of 310 helical structures in short-pHLIP at low pH in membrane. 310 is a
stretched helix, where each residue increases the length of the helix by 2 Å in contrast
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to 1.5 Å as in an -helix. Thus, the presence of 310 helical structures would help to
reduce the mismatch. At the same time, the lipid bilayer might change thickness to
match to the peptide length. To investigate potential changes, which might occur in the
lipid bilayer when polypeptides interact with it, we carried out SAXS measurements
on POPC liposomes in the absence and presence of long and short pHLIPs at high and
low pHs. We used small (about 80 nm in diameter) and larger (about 120 nm in
diameter) POPC liposomes. From the SAXS data, only the bilayer form factor was
analyzed and the full vesicle scattering function was not included in the model.

The main features of the bilayer form factor of POPC liposomes in the presence of
short-pHLIP at pH 8 (blue lines, Figure 4a, b) were very similar to that of original
liposomes (black lines on Figure 4). At low pH, the maximum of the bilayer form
factor of POPC liposomes in the presence of short-pHLIP (red lines Figure 4a, b) was
shifted and became broader, indicating that the insertion of the peptide into the
membrane caused a change in the bilayer structure. In contrast to the changes
associated with short-pHLIP interaction with bilayer, the most significant changes of
the bilayer form factor of liposomes was observed when long-pHLIP partitions into
bilayer as an asymmetric inclusion at pH 8 (blue lines, Figure 4c, d). At low pH, when
long-pHLIP inserts into membrane as a TM helix, the changes of the bilayer form
factor was minimal compared to the form factor of liposomes in absence of the
peptide.
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Since, multilamelar features were observed for 120-nm liposomes (Figure 4b, d), only
the data obtained with 80-nm liposomes was used for further analysis (fitting) to
minimize the number of variable parameters. We employed a Gaussian model to
describe electron density profiles [Eq. (1)]. The fitting was performed for the ED
profiles obtained in different experiments with different concentrations of peptides and
lipids. The representative fits are shown in Figure 5a-e. Table 2 summarizes the mean
and standard deviation of the parameters calculated from the Gaussian fitting of SAXS
data obtained in different experiments. The fitting of the data for short peptide in the
presence of POPC at pH 8 proved to be the most problematic (the highest discrepancy
between the fitting curves and experimental data). This is most likely due to the
presence of free peptides, which was expected since truncated peptides have a lower
binding affinity to the bilayer at pH 8 (8). The bilayer thickness for liposomes alone
was set as 100%. The thinning of bilayer of liposomes calculated for different
experiments were averaged and presented in Figure 5f. The electron density profile for
POPC liposomes in the absence and presence of peptides are shown in Figure 5g, h.
We observed an increase of electron density in the outer leaflet and in the middle of
the bilayer and about 12% of bilayer thinning for POPC liposomes in the presence of
long peptide at pH 8.0, when it partitions into the membrane in the form of random
coil. At low pH, when long-pHLIP forms TM helix, the thinning is released. The
short-peptide does not partition as deep into membrane as long-pHLIP and has a lower
affinity to the bilayer at high pHs, thus the thinning is about twice less (7 %). The
strongest thinning of the membrane by about 18% is observed in the case of short
peptide insertion into bilayer at low pH. The significant membrane thinning at low pH
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can indicate on insertion of short-pHLIP into bilayer. We can conclude that membrane
thinning occurs to reduce a hydrophobic mismatch and an overall energy of the
system.
Analysis of SAXS data
The scattered intensity can be expressed as I(q)F(q)2 (23), where F(q) is the size
averaged scattering form factor of vesicles, which is the Fourier transform of the
bilayer electron density profile. By describing the electron density (ED) profile along
the normal of the phospholipid bilayer of outer leaflet headgroups, hydrocarbon tails
and inner leaflet headgroups as a sum of Gaussian functions (23-27):

𝜌(𝑧) = ∑𝑛𝑘=1 𝜌𝑘 ∙ 𝑒𝑥𝑝 [−

(𝑧−𝑧𝑘 )2
2𝜎𝑘2

]

(1)

we can obtain the following expression for the scattered intensity:

𝐼(𝑞) ∝ 〈𝐹(𝑞)2 〉 =
−𝑞 2 (𝜎𝑘2 +𝜎2′ )

𝑞 −2 ∑𝑘,𝑘 ′ (𝑅0 + 𝑧𝑘 )(𝑅0 + 𝑧𝑘 ′ )𝜌𝑘 𝜌𝑘 ′ 𝜎𝑘 𝜎𝑘 ′ ∙ 𝑒𝑥𝑝 (

𝑘

2

) cos(𝑞(𝑧𝑘 − 𝑧𝑘 ′ ))
(2)

where k, zk and k are the relative weight, position and width of the k-th Gauss
function, respectively. For the bilayer k = 1 represents inner headgroups, k = 2
represents hydrocarbon tails, and k = 3 represents outer headgroups. We assume that
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the center of the bilayer coincides with the center of the hydrocarbon tail, which
means z2 will be close to zero. The ED of liposomes in absence and presence of
peptides was fitted by the sum of exponential functions. Fitting was performed using
Origin 9.0. The best fit was defined as the one with the smallest 2.

Discussion
Previously we established that at the low lipid:peptide ratios we used in this study, the
peptide is adsorbed to 50-60 lipids on average and an additional 50–60 lipids are
perturbed. In contrast, a peptide in the transmembrane state III is estimated to affect
only ~22 lipids, roughly one layer around the helix (10). Also we showed that longpHLIP interacting with the biological membranes of human red blood cells (RBCs) at
neutral pH induces appearance of spicules on the surface of the majority of cells (no
leakage of hemoglobin by RBCs was observed) (28). The formation of spicules when
the peptide is bound to the membrane was interpreted as the consequence of extra area
occupied by pHLIP on the outer leaflet of the lipid bilayer. At pH 6, i.e., when a
higher population of the peptides inserted into the membrane, the number of spikes is
greatly reduced. A related observation was obtained from lipid fluidity measurements
by the fluorescence anisotropy of TMA-DPH incorporated into the bilayer of
membrane (19). The results of SAXS measurements indicate a 12% and 7% thinning
of the lipid bilayer when long-pHLIP or short-pHLIP occupy the outer leaflet of
bilayer at high pH, respectively, compared to the same liposomes with no peptide. Our
results are also in agreement with the data obtained by Huang and co-authors
indicating that amphipathic peptides, which adopt helical conformation at the surface
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of bilayer, induce membrane thinning (29, 30). When a peptide is adsorbed into the
surface of a bilayer, it pushes the lipid headgroups aside. Since the total volume of the
chains is constant, this causes the membrane to thin. Thus, polypeptide that is
adsorbed by a bilayer even in coil conformations, like in the case of pHLIPs, induces
some membrane tension and stress, which leads to the membrane thinning. The
interaction of short pHLIP with a membrane causes the membrane thinning to a lesser
extent, since the affinity of truncated pHLIPs to lipid bilayer at pH 8.0 is lower (8),
and according to the results of dual quenching and NBD-FRET assays short-pHLIP
does not partition into a bilayer as deep as long-pHLIP. Our previous kinetics studies
demonstrated the formation of a helical intermediate on the surface of a membrane
during the folding and insertion of the long-pHLIP across the membrane (11). We
suspect that the membrane thinning may reach a maximum value, when long-pHLIP
transforms from coil configurations to the helical membrane-surface orientations. The
transition from the helical membrane-surface conformations to the stable TM could be
driven by the release of membrane tension and the restoration of the original
membrane thickness. We propose to carry out kinetic SAXS measurements to monitor
changes in the lipid bilayer of the membrane during pHLIP insertion and folding into
the membrane.

When long-pHLIP inserts into a membrane at low pH, the thickness of bilayer is
restored. However, at low pH in the presence of short peptide the membrane thins by
about 18% of its original size. Low pH induces protonation of Asp/Glu residues and
promotes propagation of the short-pHLIP into the bilayer. Our data indicates that the
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peptide spans the bilayer. Since the peptide has a truncated TM part, its insertion into a
membrane is expected to lead to a negative hydrophobic mismatch. As it was
proposed early, there are number of ways a system might reduce negative energy of
hydrophobic mismatch, such as the thinning of lipids, aggregation of peptides and
stretching from the alpha-helical to 310-helical conformations. The ideal alpha-helix
has a periodicity of 3.6 residues per turn, encloses 13 atoms in a ring by formation of
an i, i + 4 C=O:::H-N hydrogen bonds, making it a 3.613-helix. The 310-helix is a more
tightly wound less stable helix, stabilized by i, i + 3 C=O:::H-N hydrogen bonds.
However, there is no disallowed region between the alpha-helical and the 310-helical
conformations in the Ramachandran plot, and therefore transitions between helices can
easily occur (44). Furthermore, the hydrophobic environment of protein interiors or
lipid membranes could stabilize the 310-helix (45). There is a high probability to
observe 310-helical segments as N- and C-terminal capping of an alpha-helix. The
mixture of helical structures in a membrane and their transition from one to another
was demonstrated to be important for biological function (31-34). Our data does not
point to the aggregation of the peptide in membrane; however we cannot exclude that
as a possibility. We can confirm the thinning of a bilayer as measured in SAXS
experiments and the formation of a stretched 310 helix or most probably mixture of
alpha- and 310-helices with 310 components at the beginning and end of alpha-helix.
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Tables
Table 1. The percentage of quenching of Trp fluorescence of long-pHLIP and shortpHLIP in the presence of POPC liposomes at pH 8.0 and pH 4.0, by acrylamide and
10DN incorporated into liposomes. The data are calculated from the spectra shown on
Figure 2.

pH 8.0

pH 4.0

Acrylamide

10-DN

Acrylamide

10-DN

Short-pHLIP

79.1%

12.3%

48.1%

34.7%

Long-pHLIP*

44.1%

32.7%

31.1%

44.6%
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Table 2. The mean and St.D. of the parameters calculated from the Gaussian fitting of
several SAXS data obtained in different experiments. The mean and st.d. are shown in
the Table. k, zk and k are the relative weight, position and width of the k-th Gauss
function, respectively. For the bilayer k = 1 represents inner headgroups, k = 2
represents hydrocarbon tails, and k = 3 represents outer headgroups. We assume that
the center of the bilayer coincides with the center of the hydrocarbon tail, which
means z2  0±0.5 nm. The R2 varied in the range of 0.980 to 0.999 for all fits. The last
row contains values of lipid bilayer thickness, d, calculated from the difference
between z1 and z3.

POPC

Long + POPC,

Long + POPC,

Short + POPC,

Short +

pH 8.0

pH 4.0

pH 8.0

POPC, pH
4.0

z1

2.14±0.14

1.80±0.02

2.09±0.01

1.75±0.21

1.69±0.01

z2

0.24±0.26

-0.17±0.33

0.15±0.50

-0.44±0.51

-0.31±0.27

z3

-2.23±0.16

-2.03±0.04

-2.14±0.06

-2.30±0.28

-1.89±0.02

1

2.68±0.29

3.00±0.00

3.10±0.13

3.75±0.21

2.90±0.14

2

-2.00±0.00

-2.00±0.00

-2.00±0.00

-2.23±0.39

-2.00±0.00

3

2.63±0.46

2.80±0.01

2.92±0.45

2.84±0.27

2.70±0.14

1

0.232±0.104

0.315±0.092

0.196±0.085

0.202±0.047

0.577±0.043
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2

0.326±0.007

0.501±0.156

0.377±0.122

0.434±0.136

0.900±0.141

3

0.114±0.028

0.107±0.004

0.191±0.129

0.112±0.053

0.316±0.042

d

4.37±0.03

3.83±0.04

4.23±0.04

4.05±0.07

3.58±0.01
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Figures

Figure 1. Three states of short-pHLIP. The states were monitored by changes of
tryptophan fluorescence (a) and CD (b). The state I (black lines) represents peptide in
solution at pH 8.0. The state II (blue lines) is a peptide in a solution in the presence of
POPC liposomes at pH 8.0. The state III (red line) is a peptide in a solution in the
presence of POPC liposomes at pH 4.0.
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Figure 2. Dual-quenching assay. The tryptophan fluorescence of short-pHLIP (a, b)
and long-pHLIP (c, d) in the presence of POPC liposomes at pH 8.0 (blue lines) and
pH 4.0 (red lines) are shown. The emission of tryptophan residues of the peptides in
the presence of POPC liposomes at both pHs is quenching by 10DN (magenta lines) or
acrylamide (green lines). The amount of quenching is given in Table 1.
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Figure 3. NBD-FRET assay. The tryptophan fluorescence of short-pHLIP (a, b) and
long-pHLIP (c, d) in three states are shown. We used asymmetrically-labeled (by
NBD) POPC liposomes to record spectra of peptides in the states II and III. Energy
transfer from tryptophan residues to NBD dye at the inner leaflet of bilayer was
monitored (b, d). The numbers on panels b and d indicate the increase of NBD
fluorescence in states III and II compared to the baseline (black lines).
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Figure 4. SAXS intensities obtained from the POPC liposomes (80 nm (a, d) and
120 nm (b, d) in diameter) alone (black lines), the peptides at pH 8.0 (cyan lines) and
pH 4.0 (magenta lines), the peptide in the presence of POPC liposomes at pH 8.0 (blue
lines) and pH 4.0 (red lines) are shown. These are the representative data showing
only the bilayer form factor.
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Figure 5. Fittings of SAXS data. The averaged buffer background was subtracted
from each intensity profiles of liposomes in the absence and presence of long and
short peptides. The fitting was performed using Gaussian electron density model of
lipid bilayer for POPC liposomes (80 nm in diameter) in the absence and presence of
peptides at different pHs (a-e). The averaged fit parameters are given in the Table 2.
The representative data are shown. The mean and st.d. for the percentages of bilayer
thinning for long- and short-pHLIPs in the presence of POPC at pHs 8.0 and 4.0 are
shown on panel f. The electron density profiles of bilayer of POPC liposomes in the
128

absence and presence of long-pHLIP (g) and short-pHLIP (h) at pHs 8.0 and 4.0 are
presented.
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Abstract
It is important to measure pH at the surface of cells in diseased tissue with accuracy
and precision, since acidity is associated with the development of various pathological
states including tumors, ischemic stroke and acidity has the lowest pH at cell surface.
We have introduced a novel approach of extracellular pH measurements at the surface
of cells, which is based on the use of a pH-sensitive fluorescent dye SNARF
conjugated to a pH Low Insertion Peptide (WT-pHLIP), which targets plasma
membranes of cells in acidic diseased tissue. Our experimental set up includes two
different approaches, one is based on acquisition of fluorescent spectra, and other one
is based on recording of images via two emission filters. By using appropriate
calibration curves obtained on liposomes and tumor spheroids in the presence of 2deoxyglucose, both approaches give the same values of surface pH. The developed
tool was validated on cancer cells grown in tumor spheroids, in mice and excised
tumors ex vivo. We establish that highly metastatic cancer cells have lower pH at their
surface compared to non-metastatic cells. Our approach was sensitive enough to detect
pH changes in vitro and in vivo induced by glucose, which leads to the enhancement
of cancer cells metabolism and acidification of the extracellular space. The introduced
tool could be developed for clinical application of surface pH measurements in biopsy
samples. It might provide important clinical information about tumor stage and
invasiveness, and can guide in the choice of treatment approach.
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Introduction
Acidity is associated with development of various pathological states such as tumors,
ischemic stroke, neurotrauma, epileptic seizure, inflammation, infection, wounds and
others(1-3). Thus, it becomes increasingly important to be able to measure pH with
accuracy, precision, and high spatiotemporal resolution in experimental systems of
cell culture, animal models and in human beings.

The pH electrodes are used for accurate pH measurements in solution. As such
microelectrodes were the first method used to probe pH in living tissue. However they
are highly destructive to the tissue and are weighted to the extracellular pH(4, 5). Later
on noninvasive pH measurement methods were developed that could measure either
the pHi, intracellular pH, pHe, extracellular pH, or both. PET has been used for
measuring tissue pH using radiolabeled dimethadione, which distributes in
intracellular and extracellular space according to the pH gradient across membranes
(6). Unfortunately, dimethadione’s distribution depends on the transmembrane pH
gradient and the fractional volumes of intra- and extracellular space, both of which are
unknown. In vivo MRS and MRI have been used to monitor metabolic and physiologic
processes employing endogenous and exogenous nuclear MR–active compounds (7).
MRS methods are generally based on a difference in chemical shifts between pHdependent and -independent resonances. Several isotopes have been evaluated to
determine tissue pH with MRS.
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P-MRS provides a robust technique for

simultaneously measuring pHi from the chemical shift of endogenous inorganic
phosphate and pHe from the chemical shift of exogenous indicators, such as 3-
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aminopropyl phosphonate (8). Tumor pH was also measured using hyperpolarized 13C
bicarbonate (9, 10). One of the limitations of dynamic nuclear hyperpolarization is that
the hyperpolarized nuclear spin signal decreases rapidly according to spin-lattice
relaxation, T1. Therefore, measurements must be completed within 1–2 min after
injection. Another approach using MRI relies on perturbing the relaxivity of water via
pH-dependent relaxation agents such as tetraphosphonate, gadolinium-DOTA4AmP52 (7, 11).

The described above studies showed that tumor pHe is heterogeneous and acidic.
However, these methods are still limited in spatial resolution and cannot measure pH
on a cellular level. Only optical methods can provide cellular resolution. Fluorescence
imaging was employed to study pH at the surface of cultured cancer cells and monitor
behavior

of

individual

fluorescent

cancer

cells

in

the

heterogeneous

microenvironments of tumors (12-16). For pH-imaging mostly pH-sensitive dyes,
fluorescence intensity of which is changed in a response of pH, are used. However,
accurate calibration for the probe concentration is needed. pH-sensitive and pHinsensitive fluorophores were used to functionalize the bacteriophage particles with
many copies of these dyes and perform in vivo imaging

(15). However, the

bacteriophages particles are taken by endocytosis, thus reporting pH primarily in
endosomes. Fluorescence lifetime imaging is based on measurements of a
fluorophore’s excited state lifetime, which changes in accordance with pH alterations.
However, lifetime measurements are more complicated, especially for the
measurements in the nano sec range, which is a typical lifetime of most of organic
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dyes (including pH-sensitive ones). One of the approaches is to use long-lived (micro
seconds) metal-chelate complexes (they mostly exhibit phosphorescence signal).
However, most of them have short wavelength of excitation (<450 nm), which has low
tissue penetration (17, 18). Despite the fact that optical imaging can provide singlecell resolution in vivo, in order to measure pH on the surface of individual cell the pHsensitive probe needs to be located close to the plasma membrane. In most cases, the
pH-sensitive agents were small molecules distributed in entire organ/tissue and blood
(where pH is normal) and washed out from the body very quickly. In case of use of
nanocarries (nanoparticles or bacteriophage particles), cells internalize them readily
via endocytotic pathway, thus pH could be reported predominately in endosomes. The
use of antibody or receptor targeting peptides/molecules could also lead to their
internalization. The lipids or fatty acids conjugated with pH-sensitive probes (13, 19)
could be used for pH measurements on cellular level, but they are not selective to cells
in disease site, they will incorporate into any cellular membrane, and can readily
undergo flipping and participate in lipid exchange, thus making problematic
identification of their exact location, especially in in vivo experiments.

We propose a novel approach of pH measurements at the surface of cells, which is
based on use of a pH-sensitive fluorescent dye SNARF conjugated to a pH Low
Insertion Peptide (pHLIP). Peptides of pHLIP family insert into the lipid bilayer of a
membrane in a pH-dependent manner exposing N-terminus to the extracellular space
and translocating C-terminus across membrane into cytoplasm (20-23). The molecular
mechanism of pHLIP action is based on protonation of Asp/Glu residues, which
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enhance peptide hydrophobicity and promotes membrane-associate folding and
formation of transmembrane helix (24, 25). pHLIP labeled with optical, PET or
SPECT probes target acidic diseased tissue and are considered to be novel acidity
markers (26-33). A novel tool for mapping pH at the extracellular surface of cell, we
introduced here, might open an opportunity to contribute in understanding of diseases
progression and development of approaches of pH-based image-guided interventions.

Materials and Methods
Peptide Synthesis and Conjugation with Fluorescent Dyes
A pHLIP peptide with a single Lys residue at the N-terminus (the N-terminus is
acytilated):

Ac-AKEQNPIYWARYADWLFTTPLLLLDLALLVDADEGT

was

synthesized and purified by reverse phase chromatography by CS Bio. SNARF-1
carboxylic acid, acetate, succinimidyl ester (Life Technologies) was conjugated to
pHLIP at a ratio of 2:1 in 60% DMF (dimethylformamide), 30% 0.1 M PBS pH 9.0
and 10% pH 9.5 0.1 M sodium bicarbonate buffer for a final pH of 9.0. SNARF-1 was
converted to its fluorescent form after conjugation by raising the conjugation
solution’s volume by 50% with methanol and raising the solution pH to 14 with 2 M
potassium hydroxide for 1 hour. The reaction progress was monitored by reverse
phase (Zorbax SB-C18 columns, 9.4 × 250 mm 5 μm, Agilent Technology) highperformance liquid chromatography (HPLC) using a gradient of 25−75% acetonitrile
and water containing 0.05% of trifluoroacetic acid. The concentration of each labeled
peptide in buffer was determined by SNARF-1 absorption at 548 nm, ε548=27,000 M-1
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cm−1. The purity and characterization of the constructs was performed by analytical
HPLC and SELDI-TOF mass spectrometry.

Phosphate Buffered Solutions
Phosphate buffered solutions were created by mixing 0.5 M dibasic and mon-basic
solutions (J.T. Baker) to obtain desired pH in the range of 5.5 to 8.0. The final PBS
solutions (experimental PBS) used in experiments contained 10 mM of phosphate, 150
mM NaCl (J.T. Baker), 0.2 mM MgCl2 (Sigma) and 0.2 mM CaCl2 (Sigma) were
added. The pH of the final solution was measured with a microelectrode pH meter
(Thermo Scientific). Buffer solutions
were sterilized by passing them through a 200 µm filter.

Liposome preparation
Large unilamellar vesicles were prepared by extrusion. 2.5 mg POPC (1-palmitoyl-2oleoyl-snglycero-3-phosphocholine, Avanti Polar Lipids, Inc.) lipids were dissolved in
0.5 mL chloroform and desolvated on a rotary evaporator and dried under high
vacuum for 3 hours. The phospholipid film was then rehydrated in pH 7.4
experimental PBS, vortexed for 5 minutes, and repeatedly extruded through a
membrane with a 50 nm pore sizes.

Cell lines
Human cervical adenocarcinoma HeLa, human melanoma M4A4, human melanoma
NM2C5 and mouse breast cancer 4T1 cell lines were purchased from the American
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Tissue and Culture Collection (ATCC). All lines were propagated in DMEM
(Dulbecco's Modified Eagle Medium) containing 4.5 g/L D-glucose and 40 mg/L
sodium pyruvate supplemented with 10% FBS (fetal bovine serum) (Gibco),
ciprofloxacin-HCl (10 µg/mL) (from Cellgro, Voigt Global Distribution) in a
humidified atmosphere of 5% CO2 at 37°C.

Tumor Spheroids
150 µL of 1% agarose (Sigma) in x1 strength PBS pH 7.4 (Gibco) was pipetted into
each well of a 48 well flat bottom tissue culture plate (Celltreat). After the agarose gel
had sufficiently settled (~1 hour), 200 µL of DMEM supplemented with 10% FBS,
ciprofloxacin-HCl was then added to each well. The covered tray was then left in a
humidified atmosphere at 37˚C, 5% CO2 for 24 hours. Next a suctioned glass Pasteur
pipette was used to remove excess media from the agarose layer. Then 200 µL of the
same DMEM with 10,000 HeLa, NM2C5 or M4A4 cells were seeded into each well
and kept in a humidified atmosphere of 5% CO2 at 37°C for 3-4 days. In case of
matrigel (Corning) use, it was dissolved on ice in DMEM at a concentration of 2.5%
(would be diluted till 2% once added to well) and then heated to 37˚C before
combining with cells to be seeded.

Tumor Mouse Models
All animal studies were conducted according to the animal protocol AN04-12-011
approved by the Institutional Animal Care and Use Committee at the University of
Rhode Island, in compliance with the principles and procedures outlined by NIH for
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the Care and Use of Animals. Subcutaneous tumors were established by injection of
HeLa, M4A4, NM2C5 and 4T1 cells (8 × 105 cells/0.1 mL/flank) in the right flank of
adult female athymic nude mice (for implanting of human cancer cell lines: HeLa,
M4A4 and NM2C5) and adult female BALB/c mice (for implanting of murine cancer
cell line, 4T1). Mice were about 20−22 g and were obtained from Harlan Laboratories.

Imaging Tumor Spheroids
The spheroids of a given cell line were incubated with 5 µM of SNARF-pHLIP into
50 µL of pH 6.3 experimental PBS buffer either with 25 mM D-glucose (glucose) or
50 mM 2-deoxyglucose (2DG) in an open Eppendorf in a humidified atmosphere of
5% CO2 at 37°C for 30 minutes. The spheroids were then washed 3 times with 1 mL
of experimental PBS of a pH that was desired for the observation. The spheroids were
then placed into an open Eppendorf with 1 mL of same PBS followed by washing with
PBS containing either 25 mM glucose or 50 mM 2DG for 15 minutes. The spheroids
were transferred to a single well of a glass bottom 96 well cell tray and fluorescence
signal was obtained onto an inverted epi-fluorescent microscope (Olympus IX71)
using 20x objective. Both spectra and images of the SNARF-pHLIP from tumor
spheroids were obtained using the same excitation filter of FF01-531/40-25 (Semrock)
with transmittance at 531 ± 20 nm. The fluorescence spectra from tumor spheroids
were recorded by an Solis software (Andor) after emission from the sample was
passing through a long pass emission filter of BCP01-568R-25 (Semrock)with
transmittance at 580 nm and higher and an shamrock SR-303i-B spectrograph (Andor)
with a diffraction grating of 300 l/mm blaze 500 nm, 400 µm entrance slit and a
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NewtonEM EMCCD (Andor) camera thermoelectrically cooled to -60˚C. Spectra were
taken every several minutes until 3 in a row were identical. After spectra recording,
the fluorescent images were acquired using Qcapture software by a Retiga-SRV CCD
(Qimaging) with two emission filters FF01-580/14-25 (Semrock) and FF01-640/14-25
(Semrock) with transmittance at 580 ± 10 nm and 640 ± 10 nm, respectively.

Trypan Blue Assay
Trypan blue solution (Sigma) at concentration of 0.67 M in experimental PBS of pH
7.0 was added to a HeLa spheroid, which was incubated with SNARF-pHLIP as
described above, in a glass bottom collagen coated cell dish (MatTek). The
fluorescence spectra and images before and immediately after addition of Trypan Blue
were taken as described above with 20x objective.

In vivo Imaging of Tumors
When tumor reached 5-8 mm in diameter, mouse was subjected to a starvation (no
food) for 24 hours before a single tail vein injection of 4 nmol (100 μL of 40 μM) of
SNARF-pHLIP in PBS was performed. At 4 hours after construct administration, the
skin was removed from tumor site under ketamine/xylazine anesthesia and mouse
tumor was placed onto a 24 x 60 mm NO 1 thickness glass slide and imaged on
fluorescent microscope using objective with 20x magnification as described above.
The SNARF-pHLIP fluorescent spectra and images were taken from various areas of
tumor before and after an intra-peritoneal injection of 125 mg of glucose (125 mg in
220 µL of PBS pH 7.4). After in vivo imaging animal was euthanized by cervical
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dislocation and tumor was excised, cut in half and fluorescence spectra and images
were acquired immediately as described above.

Ex vivo Imaging of Tumors
When tumor reached 5-8 mm in diameter mouse was euthanized and tumor was
excised. The tumor was cut into slices and placed into 150 µL, 1 µM solution of
SNARF-pHLIP experimental PBS of pH 6.3 with either no glucose or 25 mM glucose.
The slices were left to incubate with SNARF-pHLIP for 1 hour and washed 3 times
with 150 µL of experimental PBS of pH7.4 with 15 minutes between washings. Then
slices were placed into glass bottom dish and imaged on an inverted epi-fluorescent
microscope with 20x objective. Spectra and images were acquired in the same manner
as described above.

SNARF-pHLIP Liposome Calibration
300 µL of 1 µM SNARF-pHLIP and 200 µM of POPC liposomes were mixed into pH
7.4 experimental PBS and left to incubate over night at 4˚C. The pH was adjusted by
adding 0.5 M hydrochloric acid or 2 M of potassium hydroxide and final pH of the
solution was measured with a microelectrode pH meter (Thermo Scientific). The
solution was placed into a glass bottom collagen coated cell dish (MatTek) and imaged
on a fluorescent microscope with an objective of 20x magnification. Images and
spectra were taken in a similar manner as described above.

Spectra and Image Analysis
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The fluorescent spectra and images of SNARF were analyzed by our programs. The
spectra were analyzed with a Mathematica program (Version 10, Wolfram), and
images were analyzed using Matlab program (Mathworks) both introduced by us. The
description of the program is provided in the Result section. All graphs were
constructed using Origin Lab (Version 9.1, Origin Lab Corporation). The p-level
values were computed based on the two-tailed test.

Results
Various pathological states are associated with extracellular acidity. There is a proton
gradient, which decays with the distance from a cell in acidic areas. Thus, the lowest
values of pH are expected to be at the surface of cells. We have developed a novel tool
for pH measurement at the surface of cells and validated it in vitro on liposomes,
different cancer cell lines grown in tumor spheroids, in vivo in mice and ex vivo on
tumor and muscle tissue samples. Among cancer cell lines we selected highly
metastatic human cervical adenocarcinoma HeLa, and two human melanoma cell
lines, M4A4 and NM2C5, derived from the same origin, MDA-MB-435, where M4A4
is a highly metastatic, while NM2C5 is non-metastatic(34, 35).

Our approach to measure pH at the surface of cells is based on use of WT-pHLIP,
which inserts into a cellular membrane and forms a transmembrane helix translocating
the C-terminal end into the cytoplasm and exposing the N-terminal end to the
extracellular space. Additionally the pHLIP has multiple protonatable residuesat the
membrane-inserting C-terminal end, which are deprotonated in the cytoplasm and
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serve as additional anchoring point for the peptide in membrane. Thus, once WTpHLIP is inserted into a plasma membrane, the rate of its exit from membrane is very
low even when extracellular pH is raised. This opens up an opportunity to treat cells
with WT-pHLIP at low pH and then raise pH of media for measurments.

The

acetylated N-terminus of the peptide contains a single Lys residue, which was
conjugated with a SNARF-1 dye and this dye was subsequently converted to its
fluorescent form by chemical activation. The product was purified and characterized
and used in all experiments.

Our choice of ratiometric pH-indicator, SNARF, was dictated by the fact that pH
values could be established independent of the dye’s concentration, which was used
previously to measure pH in vivo (16). SNARF also has other desirable characteristics
such as high excitation and emission wavelengths, two fairly fluorescent peaks and it
runs in a single excitation dual emission configuration. The SNARF-pHLIP was
excited by the xenon lamp attached to the inverted epi-fluorescent microscope in the
range of 531 ± 20 nm as selected by an excitation filter. The emission was detected by
two different set ups: i) fluorescence was passed via emission cut off filter for the
detection of light at wavelengths from 580 nm and higher. The spectrograph connected
to the microscope allowed to record entire fluorescence spectra from 500 to 800 nm
simultaneously (Figure 1A). Our program in Mathematica performs a smoothing of
spectra and establishes the emission maximums of the SNARF-pHLIP and their ratio
𝐹595±1 −𝑏𝑎𝑐𝑘𝑔𝑟𝑜𝑢𝑛𝑑
𝐹645±1 −𝑏𝑎𝑐𝑘𝑔𝑟𝑜𝑢𝑛𝑑

. While recording of spectra is very useful, it does require special

instrumentation. For that reason it is more practical to acquire images. Thus, another
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approach we developed is based on acquisition of two fluorescent images via two
emission filters 580 ± 7 nm and 640 ± 10 nm (Figure 1B, C). We designed program in
Matlab, called Cell Fluorescence Analysis (CFA), for image analysis. First, it aligns
580 nm and 640 nm emission images on a pixel by pixel basis. The CFA program is
based on the identification of the position of individual cells by looking for high
contrast around cell edges. It uses a threshold value for the size of a cell to exclude
any signal coming from objects smaller in size than a cell. Next, pixel-by-pixel
background subtraction is processed, followed by thecalculation of an average
intensity within a cell and 580/640 nm ratio values.

The main idea of our approach is to measure pH at the surface of cells. To prove that
SNARF is indeed located in the extracellular space we imaged cells in HeLa tumor
spheroids before (Figure 2A) and immediately after (Figure 2B) treatment with
membrane-impermeable Trypan Blue, which is capable of quenching of emission of
fluorophores in the range of 500-600 nm (36). The fluorescence of the SNARF-pHLIP
in this region was completely quenched indicating that SNARF is located in the
extracellular space. The spectra of the SNARF-pHLIP before and after addition of
Trypan Blue are shown on Figure 2C (the emission at 680 nm is associated with
Trypan Blue). The bright field images of cells indicated that the vast majority of cells
were viable.

A critical step is the identification of calibration curves to transfer 595/645 ratio values
into pH values. The ratio of emission at 595 nm to 645 nm was calculated from the
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fluorescence spectra of the SNARF-pHLIP treated with POPC liposomes at various
pHs, which were recorded under microscope. The ratios were used to establish a
calibration curve, since pH in bulk of the solution, at the surface of liposomes, where
most of the SNARF-pHLIP is located, and even inside a liposome are equilibrated
quickly (25, 37). We could not exclude the possibility that the SNARF signal and thus,
calibration curve, might be different when the SNARF-pHLIP is located at the surface
of real cells, which would not be unexpected given that nigericin calibrated
intracellular SNARF curves differ from that of SNARF in solution(38)Therefore, we
used 3 cell lines, HeLa, M4A4 or NM2C5, treated with the SNARF-pHLIP to record
the spectra at various pHs. However, to establish the calibration, pH at the surface of
cancer cells needs to be equilibrated with bulk extracellular pH, which could be
achieved by preventing pumping of protons into extracellular space. This situation can
be achieved by incubating tumor spheroids before imaging with 50 mM of nonmetabolizable analog of glucose, 2-deoxyglucose (2DG). Treatment of cancer cells
with 2DG inhibits fermentative metabolism and hence the proton production and
proton flux, as confirmed previously using the Seahorse extracellular flux analyzer
(39). Indeed, all 3 cell lines demonstrated the same ratio of the fluorescence at
595/645 nm, which coincides with the ratios obtained on liposomes (Figure 3A). We
used the obtained liposome data to introduce a calibration curve, since pH at the
surface of liposomes and cells treated with 2DG is the same as pH of the bulk solution,
which could be controlled. The linear fitting was performed to establish the calibration
curve:
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𝑝𝐻𝑠 𝑠𝑝𝑒𝑐𝑡𝑟𝑎 = (8.459 ± 0.031) − (1.223 ± 0.024) ∙ 𝑅𝑎𝑡𝑖𝑜595/645 𝑠𝑝𝑒𝑐𝑡𝑟𝑎
(1)
Since fluorescent images are obtained at different experimental settings and processed
by different mathematical algorithm, we established separate calibrations curve
(Figure 3B):
𝑝𝐻𝑠 𝑖𝑚𝑎𝑔𝑒𝑠 = (8.221 ± 0.035) − (1.191 ± 0.030) ∙ 𝑅𝑎𝑡𝑖𝑜580/640 𝑖𝑚𝑎𝑔𝑒𝑠
(2)
Thus, equations (1) and (2) will be used for the processing of fluorescence ratios
obtained from spectra and images, respectively. The developed tool was applied to
establish pH at the surface of metastatic (HeLa and M4A4) and non-metastatic
(NM2C5) cancer cells grown in tumor spheroids in presence of 50 mM glucose, which
enhances and promotes cellular metabolism (Figure 3C). It is important to outline that
the pH at the surface of metastatic cancer cells does not increase more than value of
7.0 even when the pH of bulk solution is around 7.9. Non-metastatic cancer cells are
less acidic compared to metastatic, especially in the range of normal pH values. With a
decrease of pH we observed equilibration of cell-surface pHs and bulk pH of media.
When the pH of media is less than 6.4, the pH at the surface of cancer cells in average
did not decrease accordingly and did not dip below 6.35. The images were analyzed
by the CFA program, which establishes the pH of the most bright cells. This data was
correlated well with the results obtained by spectra analysis.
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The advantage of our approach is in its applicability for pH measurements in vivo,
since pHLIP can target acidic diseased tissue and tether imaging agents, including
fluorescent, to the surface of cells (27). To validate this approach in vivo, we grew
metastatic, HeLa and M4A4, and less metastatic, NM2C5 tumors in mice. When the
tumors reached about 5-8 mm in diameter, the mouse was placed in condition of
starvation for 24 hours in order to reduce flux of glucose to cancer cells from blood
and increase pH in the tumor as much as possible, followed by single IV injection of
the SNARF-pHLIP construct. At 4 hours post-injection, the mouse was anesthetized
and the skin was removed from the tumor site. Fluorescent spectra and images were
recorded from the tumor surface (the image is shown in Figure 4A). Then, the mouse
obtained a single IP injection of solution of glucose. It was shown previously that the
average extracellular pH decreases after glucose administration and reaches a
minimum level 0.3 pH units below the initial value (40). We observed spectra changes
after 40 minutes post-injection of glucose (Figure 4B), no further spectral changes
occurred after 40 minutes, which indicated acidification of tumor as monitored by our
approach. Finally, the animal was euthanized, tumor was excised, cut in half and
fluorescence was recorded from the center of the tumor. Figure 4C represents the
mean of the surface pHs in tumor surface before and after glucose injection and in the
center of the tumor. HeLa tumors are the most acidic even after 24h starvation period.
The mean values of surface pH in the center of HeLa, M4A4 and NM2C5 tumors are
6.51±0.22, 6.68±0.41 and 6.94±0.29, respectively with some HeLa tumors having pH
as low as pH 6.1. M4A4 and NM2C5 tumors had similar pH before glucose injection,
while pH was reduced more significantly in metastatic M4A4 tumor compared to non-
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metastatic NM2C5 tumors after glucose injection. Finally, we performed analysis of
tumor tissues excised from mice and immediately treated with the SNARF-pHLIP ex
vivo for 1 hour followed extensive washing and imaging SNARF fluorescence at 580
nm and 640 nm. Treatment was performed in PBS of pH7.4 in absence and presence
of glucose. Glucose in solution promotes cellular metabolism selectively in glycolytic,
highly metastatic cancer cells and enhances acidity near their surfaces. Thus, pHLIP
preferentially inserts into plasma membrane of cells with low pH at the surface, such
as cancer cells. At the same time, glucose does not affect significantly non-glycolytic
cells in healthy tissue, which has normal surface pH(41).

In Figure 4D we

demonstrate the mean values of the surface pHs in highly metastatic human HeLa and
murine 4T1 mammary tumor samples before and after treatment with glucose. The
surface pHs dropped on 0.2 and 0.6 pH units from pH 6.7±0.3 to pH 6.5±0.4 and from
pH 6.8±0.2 to pH 6.2±0.2 in HeLa and 4T1 tumor samples, respectively.

Discussion
Hypoxic conditions induce in a cell switch from the oxidative-phosphorylative
mechanism of energy production to the glycolytic mechanism. In addition, malignant
cancers have an elevated glucose uptake even under normal oxygen conditions, known
as “aerobic glycolysis” or the Warburg effect (42-44). Glycolysis results in much
higher level of the production of H+ and lactic acid, the byproducts, which are readily
pumped across a plasma membrane into the extracellular space and accumulate there,
in poor-perfused regions such as solid tumor and ischemic stroke (45-47). Another
contributor to extracellular acidity is associated with the expression of the carbonic
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anhydrase enzymes on the tumor cell surface, which catalyze the extracellular trapping
of acid by hydrating cell-generated CO2 into HCO3− and H+ (48, 49). All these
mechanisms contribute towards an acidic extracellular milieu favoring diseases
development and progressions. The extracellular pH of solid tumors plays one of the
essential roles in almost all steps of metastasis: more acidic tumors became highly
aggressive and metastatic (50). It was shown that the pH near the cell surface is the
lowest and acidity decays with distance from a cell (13). Thus, the pH at the surface of
a cell should reflect the best the stage of pathology development.

The tool we

introduced allow the measurement of pH at the surface of cells in acidic diseased
tissue. The method was validated on metastatic and non-metastatic cancer cells grown
in tumor spheroids and in vivo in mice. The approached is sensitive enough to detect
differences in a pH at the surface of non-metastatic (less acidic) and metastatic tumors,
and monitor enhancement of acidity and alteration of pH in vivo by injection of
glucose. The mean values of pH at the surface of cancer cells in the center of highly
metastatic (HeLa and M4A4) tumors were found to be 6.5-6.7. While pH at the
surface of cancer cells in non-metastatic tumors (NM2C5) was pH 6.9. The obtained
values are about 0.2-0.4 pH units lower than pH values of the bulk extracellular space
measured by 31P MRS in various mice and rat tumor models, which were varied from
pH 6.7 to pH 7.0 (the normal tissue pH was established to be 7.3-7.4) (51).

We demonstrated that pH at the surface of cancer cells, especially metastatic cells,
could be 0.6-0.8 pH units lower even when bulk pH is normal. It might open up an
opportunity for clinical applications of the developed tool for the measurements of
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pHs in biopsy samples. We validated our approach on mice tumor tissue samples. We
established that treatment of tumors with the SNARF-pHLIP in normal pH buffer of
7.4 in presence of glucose can reduce surface pHs on 0.6 pH unit till about pH 6.2
values. Next, we propose to validate our approach on human samples of breast and
bladder tumors obtained after surgery and correlate surface pHs with stage of tumor
development and appearance of specific markers predictive of cancer invasiveness. If
successful, it will introduce a new simple and fast clinical test, which can take about
30-40 min of biopsy sample treatment with the SNARF-pHLIP, quick washing step,
imaging and data processing. After the procedure, the sample will undergo standard
HE staining and histopathalogical analysis. The proposed method potentially might
provide important clinical information about tumor stage and invasiveness, and can
guide in the choice of treatment approach.
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Figures

Figure 1. SNARF-pHLIP spectra and images. Emission spectra of the SNARFpHLIP treated with liposomes at different pHs were recorded under inverted epifluorescent microscope connected to spectrograph (A). Fluorescent images of HeLa
tumor spheroids treated with the SNARF-pHLIP at pH6.6 were acquired using 580 ±
10 nm (B) and 640 ± 10 nm (C) emission filters. Colors are artificial.
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Figure 2. Trypan Blue assay. The SNARF-pHLIP image of HeLa tumor spheroids
before (A) and immediately after (B) addition of 0.67 M of Trypan Blue acquired via
580 ± 10 nm emission filter. The spectra of the SNARF-pHLIP treated with HeLa
tumor spheroids before and after treatment with Trypan Blue are shown in panel C.
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Figure 3. Calibration curves and pH at the surface of cancer cells in tumor
spheroids. Calibration curve obtained by linear fitting of 595/645 fluorescence ratios
of the SNARF-pHLIP treated with liposomes and HeLa, M4A4 and NM2C5 tumor
spheroids in presence of 50 mM of 2DG at different pH of media (A). Calibration
curve obtained by linear fitting of fluorescent images ratios at 580 and 640 nm of the
SNARF-pHLIP treated with liposomes in presence of 50 mM of 2DG at different pH
of media (B). The values of surface pHs obtained from HeLa, M4A4 and NM2C5
cells grown in tumor spheroids and treated with the SNARF-pHLIP in PBS of
different pH containing 50 mM of glucose calculated from spectra and images (C).
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Figure 4. pH at the surface of cancer cells measured in vivo and ex vivo on
tumors. The fluorescent image of HeLa tumor in live mice (skin is removed from
tumor site). The SNARF-pHLIP was given as a single tail vein injection (A). Changes
of the SNARF-pHLIP fluorescence spectra in HeLa tumor recorded on live animal
before and after IP injection of 125 mg glucose (B). The mean values of the surface
pHs in tumor of live animal before and after injection of glucose and in the middle of
the excised tumor after glucose injection (in vivo measurements) (C). The mean values
of the surface pHs in HeLa and 4T1 tumors excised from animal and treated with the
SNARF-pHLIP before and after incubation with glucose (ex vivo measurements) (D).
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